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resumo 
 
 
Microbioma é definido como sendo uma comunidade de microrganismos 
presente num dado ambiente, que engloba todos os microorganismos com 
seus genes e interações ambientais. O microbioma humano desempenha um 
papel importante na fisiologia humana e no seu metabolismo, estando 
associado ao desenvolvimento, nutrição, imunidade e resistência a agentes 
patogénicos com implicações na saúde e doença. 
A doença pulmonar obstrutiva crónica (DPOC) é uma doença pulmonar 
caracterizada por uma obstrução das vias aéreas persistente progressiva e 
não reversível. O papel das bactérias como potencial fator patogénico e 
etiológico na DPOC tem sido tema de debate nos últimos anos. Pensa-se que 
a colonização dos pulmões por determinadas bactérias, em pacientes com 
DPOC, é responsável pelo aumento do risco de exacerbações e perda de 
função pulmonar. 
Embora a saliva seja uma das amostras mais facilmente recolhida, são ainda 
poucos os estudos para caracterizar o microbioma da saliva em pacientes com 
DPOC, e ainda menos para identificar nele biomarcadores informativos sobre o 
diagnóstico e progressão desta doença. 
O objetivo deste estudo foi implementar a metodologia que permita estudar o 
microbioma da saliva em pacientes com DPOC, compreender a dinâmica do 
microbioma da saliva no contexto de uma exacerbação e como o microbioma 
evolui depois disso. 
Para isso, utilizou-se uma abordagem metagenómica utilizando a 
sequenciação do gene 16S rRNA, para analisar 17 amostras de 7 pacientes 
com DPOC, recolhidas em 3 momentos diferentes, i.e. em exacerbação, 2 
semanas após a exacerbação e após recuperação clínica. 
Neste estudo foram encontradas e serão descritas diferenças na composição 
microbiana das amostras colhidas em tempos diferentes. Verificou-se também 
uma grande variabilidade nos resultados, com grandes diferenças entre as 
amostras colhidas de diferentes pacientes. 
Estes resultados sugerem que a saliva pode ser uma boa fonte de 
biomarcadores para a DPOC e poderá representar um avanço para a 
implementação da medicina personalizada nesta população. No entanto mais 
estudos com amostras alargadas são ainda necessários. Contudo, mais 
estudos deverão ser realizados. 
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abstract 
 
Microbiome is a community of microorganisms living in a particular environment 
that englobes all microorganisms with their genes and environmental 
interactions. The human microbiome plays a pivotal role in human physiology 
and metabolism being associated to development, nutrition, immunity, and 
resistance to pathogens and has recognized implications for health and 
disease.  
Chronic Obstructive Pulmonary Disease (COPD) is a pulmonary disease 
characterized by persistent and progressive and nonreversible airflow 
obstruction. The role of bacteria as a potential pathogenic and etiologic factor in 
COPD has been a topic of debate for many years. It is thought that lung 
colonization by particular bacterial strains, in patients with COPD, is 
responsible for the chronic bronchitis phenotype, increased risk of 
exacerbations, and loss of lung function. 
Even though saliva is one of the most easily collectable samples, few studies 
have been conducted to characterize the saliva microbiome in patients with 
COPD and even fewer to identify biomarkers that might be informative for 
disease onset and progression.   
The aim of this study was to implement the methodology to study the saliva 
microbiome in patients suffering with COPD, to understand the dynamics of 
saliva microbiome in the setting of an exacerbation and how the microbiome 
evolve after that.  
For that a metagenomic approach was carried out, using the sequencing of the 
16S rRNA gene, to analyze 17 samples from 7 patients with COPD, collected 
at 3 different time points, i.e. at exacerbation, 2 weeks after exacerbation, and 
at clinical full recovery.  
In this study, we found microbial shifts in the samples collected at different time 
points. We also detected high sample variability, especially between samples 
collected from different individuals. 
These results suggest that saliva might me a good source of biomarkers for 
COPD management and may represent an improvement to the implementation 
of personalized medicine in this population. However, more and larger studies 
must be conducted.  
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1.1. Microbiome 
 
Microbiome is a community of microorganisms living in a particular 
environment that englobes all the microorganisms with their genes and 
environmental interactions (Cox et al. 2013). The human microbiome has been 
defined as “the ecological community of commensal, symbiotic, and pathogenic 
microorganisms that literally share our body space” (Lederberg & McCray 2001). 
The human microbiome colonizes a wide range of body niches including skin and 
mucosae, gut, oral cavity, upper respiratory tract and lung. It is composed by a large 
variety of microbial communities such as bacteria, archaea, viruses, phage, fungi, 
and other microbial eukarya, being bacteria the larger fraction and the most well-
studied group (Cox et al. 2013).  
Today it is known that we have as many microorganisms as we have body 
cells, around 40 trillion (Sender et al. 2016).  Most microbes that are living in our 
body are commensals and provide us with genetic variation and gene functions that 
human cells did not evolve on their own (Grice & Segre 2012). Interestingly, the 
human microbiome plays a pivotal role in human physiology and metabolism being 
associated to development, nutrition, immunity, and resistance to pathogens with 
implications for health and disease (Sender et al. 2016; Li et al. 2012). This is why 
the human microbiome has been widely studied in the past two decades (Sender et 
al. 2016).   
The human microbiome was shown to be a dynamic population that can vary 
by the introduction or extinction of certain microbial groups or by a change in the 
population structure - known as dysbiosis (Cho & Blaser 2012). These alterations 
can be induced by selection through environmental factors, such as host dietary 
changes, antibiotics administration or exposure to pollutants (Blaser 2006). 
Dysbiosis disturb the partnership between the host immune system and the 
microbiota, and may lead to altered immune responses that may underlie several 
inflammatory disorders, such as inflammatory bowel disease, obesity, diabetes, and 
colorectal cancer  (Degruttola et al. 2016; Round & Mazmanian 2009). Therefore, 
some authors are currently considering that the interplay between the microbiome 
and human hosts represent the next frontier in medicine (Mammen & Sethi 2016). 
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Dysbiosis in the airway microbiome have been associated with multiple 
pulmonary diseases such as asthma, chronic obstructive pulmonary disease and 
cystic fibrosis (Marsland et al. 2013). To study the airway microbiome one can 
collect different types of samples, being the most common the sputum (Wang et al. 
2016; Huang et al. 2014; Millares et al. 2014; Molyneaux et al. 2013), followed by 
others such as bronchiolar alveolar lavage (BAL) (Hilty et al. 2010), lung tissue 
sample ( Sze et al. 2015; Sze et al. 2012), and oropharyngeal swab samples (Liu et 
al. 2017; Diao et al. 2017; Park et al. 2014).   
Even though they all have the goal of informing about the airway microbiome, 
the results of choosing different kinds of samples can be very divergent (Appendix 
1). As we can see on the work of Cabrera-Rubio et al. (2012), where sputum, 
bronchial aspirate (which represents the upper respiratory tract), BAL and bronchial 
mucosal biopsy (representing the lower respiratory tract), from stable patients with 
chronic obstructive pulmonary disease, were collected and compared. The results 
showed that the sputum had lower diversity than the other sample types. 
Additionally, the bronchial mucosa and BAL samples showed similar bacterial 
compositions in contrast to sputum and bronchial aspirate samples. Thus, from this 
study, it can be concluded that samples collected from the upper respiratory tract 
are not representative of the lower respiratory tract  (Cabrera-Rubio et al. 2012).  
On the other hand, there are some other authors that suggest that the 
community composition exhibits minimal variation inside the airways (Liu et al. 2017; 
Charlson et al. 2011; Charlson et al. 2010). When compared naso- and 
oropharyngeal samples and samples from the upper (oral, oro/nasopharyngeal) and 
lower airways (glottis, BAL, lower airway brush) Charlson and colleagues (2010, 
2011), and later Liu et al. (2017) with oropharyngeal and sputum samples, found 
that despite the differences in the body site, microbiomes in the airways are 
remarkably similar.  
Consistently, the oral microbiome is more similar to the lung microbiome than 
with the  microbiome present in the air (Dickson et al. 2014). This can be explained 
by the fact that the human respiratory tract is a continuous system, from the nasal 
and oral cavities to upper and lower airways, without any physical barrier (Dickson 
& Huffnagle 2015). It is believed that the movement of the microbes occurs regularly 
9 
 
via breathing, microaspiration and mucosal dispersion, and this movement is also 
bidirectional  (Charlson et al. 2011).  
A study conducted, with healthy subjects, defined a core saliva microbiome 
as composed by members of the Firmicutes phylum (genus Streptococcus, family 
Veillonellaceae, genus Granulicatella), Proteobacteria (genera Neisseria and 
Haemophilus), Actinobacteria (genera Corybacterium, Rothia, and Actinomyces), 
Bacteriodetes (genera Prevotella, Capnocytophaga, Porphyromonas) and 
Fusobacteria (genus Fusobacterium) (Zaura et al. 2009). 
When comparing the oral microbiome and BAL samples, of healthy subjects, 
lung bacterial populations have been found remarkably similar to the oral 
microbiome, even though at lower concentrations in the oral cavity (Bassis et al. 
2015). These results confirm that the bacteria from the upper airway shape the 
microbial community of lower airways of healthy subjects (Bassis et al. 2015; Morris 
et al. 2013; Pragman et al. 2012; Charlson et al. 2011), although they are found in 
lower concentrations (Morris et al. 2013; Charlson et al. 2011), and may have 
different community composition (Bassis et al. 2015).  
Therefore, the type of respiratory specimen should be considered in the 
interpretation of the results of lung microbiome studies. Nevertheless, the use of 
saliva to access markers of human health has been already described. Torres et al. 
(2015), suggested that bacteria abundance profiles in saliva may be useful 
biomarkers for pancreatic cancer. And this is also true for respiratory diseases, 
Zemanick et al. (2015), compared saliva samples with samples from the lower 
respiratory tract of children suffering with cystic fibrosis. They concluded that 
differences in the lower  and upper airways communities were associated with 
airway inflammation and may be used as biomarkers for disease progression 
(Zemanick et al. 2015). Thus, these specimen may be informative when dealing with 
respiratory as well as non-respiratory diseases (Acharya et al. 2017).    
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1.1.1 Methodologies for studying the microbiome 
Historically, cultivation and isolation of bacteria have been the unique method 
available for identification and characterization of microbes (Grice & Segre 2012). 
After isolation of a colony, bacterial have been classified by direct observation of 
bacterial cells, their morphology, their components, biochemical testing, and their 
ability to grow on different culture media (Grice & Segre 2012; Medini et al. 2008).  
However, these methodologies introduce biases, since they select only the 
microbes that grow in isolation and under specific laboratory conditions, for that 
reason the complete diversity of microorganisms remain largely unknown when 
these approaches are used (Grice & Segre 2012). It is estimated that the culturable 
organisms represent less than 2% of all the organisms within a sample (Wade 
2002). In addition, these methodologies are time consuming and expensive 
(Hugenholtz 2002). 
 In 1977, Carl Woese and George Fox proposed that it is possible to 
characterize the tree of life using genetic sequences of the small-subunit ribosomal 
RNA, such as the 16S ribosomal RNA (rRNA) gene (Woese & Fox 1977). This gene 
is a highly conserved component of the transcriptional machinery of all bacteria (Cox 
et al. 2013), and consists of a unique mosaic structure including extreme conserved 
regions and variable regions with specific evolutionary rates (Bik 2016). More 
precisely, the gene has a length of 1522 base pairs and is composed by nine hyper-
variable regions, labelled V1-V9. These regions have varied throughout bacterial 
evolution, thus being useful for taxonomic identification and evolutionary dating 
(Figure 1) (Van de Peer 1996). 
Figure 1 - 16S rRNA gene of E. coli showing the nine hypervariable regions (adapted from Cox 
et al. 2013). 
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In 1977, Frederick Sanger and colleagues developed the first DNA 
sequencing method - Sanger Sequencing or First-generation Sequencing (Sanger 
et al. 1977). This method consists of a “cycle sequencing” reaction, in which cycles 
of template denaturation, primer annealing and primer extension are performed 
(Shendure & Ji 2008). Each round of primer extension ends with the incorporation 
of a fluorescent labeled dideoxynucleotides (ddNTPs), resulting in a mixture of 
fragments that all have a last nucleotide labelled with a dye which corresponds to 
the last base inserted (Shendure & Ji 2008). Then all the fragments are separated, 
based on their length, through a capillary electrophoresis (Schadt et al. 2010). 
Afterwards, these labelled fragments pass through a detection unit, where the 
fluorophores are excited by a laser, producing fluorescence emissions of four 
different colors (based on the four different dNTPs) (Metzker 2005). The information 
about the last base is used to produce a sequence “trace” that reflects the original 
DNA sequence  (Schadt et al. 2010).  
This process results in a read length up to 1000bp, an accuracy per base of 
99,999% (Shendure & Ji 2008). Although it has some limitations, such as being time 
consuming and expensive (Schadt et al. 2010), the sequencing of the 16S rRNA 
gene with the Sanger technology came to revolutionize the study and classification 
of microorganisms (Escobar-Zepeda et al. 2015).  
Most of the existing understanding of the human microbiome still comes from 
culture-based approaches using the sequencing of 16S rRNA gene (The NIH HMP 
Working Group 2009). However, in response to the lower throughput and higher 
costs provide by the automated Sanger method, in the beginning of the 20th century 
emerged the Next Generation Sequencing (NGS) technologies. These new 
sequencing technologies have three major improvements. First, instead of requiring 
bacterial cloning of DNA fragments they depend on the preparation of NGS libraries 
in a cell-free system. Second, thousands to millions of sequencing reactions are 
produced in parallel. Third, the sequencing output is detected with no need for an 
electrophoresis (Van Dijk et al. 2014). Thus, these technologies have the ability to 
produce an enormous amount of data at a much lower cost (Metzker 2010).   
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Among the NGS technologies the most used are the Illumina sequencing by 
Illumina, the Sequencing by Oligo Ligation Detection (SOLiD) by Life Technologies, 
and the PacBio systems (Van Dijk et al. 2014).  
 With the advent of NGS technologies and bioinformatics tools, the 
determination of the global microbial ecology of a biological sample, and not just the 
evaluation of those that are able to grow on laboratory growth media, became 
possible (Mammen & Sethi 2016). These current molecular technologies allow the 
creation of an entire “community fingerprint”, by identifying members, as well as 
quantifying and estimating relative bacterial abundance within the community. This 
made possible to consider the microbial population as a whole “metagenome” by 
applying a high-throughput sequencing to the entire DNA population of a sample 
(Han et al. 2012). Globally, these processes are called metagenomics. 
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1.2 Metagenomics 
 
Metagenomics is defined as “the application of modern genomics techniques 
to the study of communities of microbial organisms directly in their environments, 
without the prior need for isolation and cultivation of individual species” (Chen & 
Pachter 2005). These allow the identification of both community members within a 
sample and their genetically encoded functional capacity (Han et al. 2012). 
Actually, the term can be used for functional and sequence-based analysis 
of the collective microbial genomes of the microbial community – shotgun 
metagenomics sequencing, or for studies performing a PCR amplification of certain 
genes, being the 16S rRNA gene the most used – amplicon sequencing 
metagenomics (Oulas et al. 2015). A summary of the two different metagenomics 
approaches is shown in figure 2. 
Shotgun metagenomics tries to answer questions such as: who is within the 
sample? What are they doing? What are they capable of doing? And how do these 
microorganisms interact with each other? However, this method requires an 
enormous informatics power since it produces large amounts of data (Oulas et al. 
2015; Sharpton 2014). 
Amplicon sequencing metagenomics or marker gene metagenomics is the 
fastest and more widely used approach to obtain a taxonomic and phylogenetical 
distribution profile of a sample (Oulas et al. 2015). However, it has some limitations 
such as the lack of phylogenetic resolution, especially with short read lengths, and 
the fact that distinct bacterial species contain nearly identical 16S rRNA gene 
sequences, that leads to widely varying estimates of diversity (Poretsky et al. 2014). 
In addition, this methodology provides information about the taxonomic composition 
of the community, but fails to recall the biological functions of these microbiomes 
within the community (Sharpton 2014). 
Nevertheless, mostly for economical reasons, sequencing the 16S rRNA 
gene is the most used approach to characterize the diversity of microbiota. Under 
the scope of this method, a community is sampled (e.g. saliva, sputum) and DNA is 
extracted from all existing cells (Sharpton 2014). Then, specific primers are used to 
14 
 
flank one or two of the hypervariable regions  and these regions are amplified 
through a polymerase chain reaction (PCR) (Huang et al. 2017; Cox et al. 2013).  
Then amplicons are sequenced through a NGS technology, which enables 
the study of many samples at low cost (Metzker 2010). After sequencing, the 
sequences are clustered into Operational Taxonomic Units (OTUs) – an operational 
definition to classify, by similarity, groups of DNA sequences as belonging to one 
species or one group of species (Blaxter et al. 2005). Typically, the similarity 
between all pairs of sequences is computed as the percentage of common bases in 
a pairwise sequence alignment – and, in order to belong to the same OTU, a group 
of sequences must normally share 97% of similarity (Mammen & Sethi 2016; 
Nguyen et al. 2016). This value was conventionally assumed to represent bacterial 
species, when using 16S rRNA sequencing (Drancourt et al. 2000). 
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Figure 2 - Metagenomics workflow. First, microbial community DNA is extracted from a sample. 
Then, two approaches can be done. Amplicon sequencing metagenomics, where the 16S 
rRNA gene is amplified and sequenced. Similar sequences are then grouped into OTUs, which 
can be compared to 16S databases to identify their species of origin. The community can be 
described in terms of which OTUs are present, their relative abundance, and/ or their 
phylogenetic relationships. The other approach – shotgun metagenomics, comprehends the 
direct sequencing of the DNA of the community. DNA reads are then compared to reference 
genomes, so that all genes present are identified and quantified. Using this approach, the 
functional capabilities of the community can also be determined by comparing the sequences 
to functional databases (Adapted from: (Morgan & Huttenhower 2012)). 
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Once OTUs are defined, one can use them to characterize the microbial 
community, in terms of alpha-diversity – which OTU’s are present within the sample 
or groups of samples i.e. richness; as well as how evenly these OTU’s are 
distributed within the sample or group of samples i.e. diversity. To study the richness 
of a sample, the most frequently applied measures are the number of OTU’s 
observed, the Chao1 estimator (Chao 1984), and the Abundance-based Coverage 
(ACE) Estimator (Morgan & Huttenhower 2012). One can also study the beta-
diversity, i.e. the similarities, or differences, in the microbial composition between 
samples. The most common metrics used to study the beta-diversity in 
metagenomic studies are the Bray-Curtis dissimilarity (Bray & Curtis 1957) and the 
UniFrac metric (Lozupone & Knight 2005) (Navas-Molina et al. 2013; Morgan & 
Huttenhower 2012). 
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1.3 Chronic Obstructive Pulmonary Disease   
 
Chronic Obstructive Pulmonary Disease (COPD) is a pulmonary disease 
characterized by persistent and progressive airflow obstruction – that is the result of 
a mixture of airway diseases, such as chronic obstructive bronchiolitis (obstruction 
of the small airways), emphysema (destruction of alveolus), and chronic bronchitis 
(mucus hypersecretion) (Barnes et al. 2015), as shown in figure 3. Consequently, 
patients with COPD suffer with persistent and progressive dyspnea, chronic cough, 
and chronic sputum production (GOLD 2017).  
 
 
 
 
Figure 3 - Comparison between lungs in healthy subjects and in patients with COPD. 
COPD is characterized by a mucus hypersecretion (chronic bronchitis), a mucosal 
inflammation and fibrosis (chronic obstructive bronchiolitis), and a destruction of 
alveolus (emphysema), source: Barnes et al. 2015. 
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According to Global Initiative on Obstructive Lung Disease (GOLD), the 
disease can be divided into 4 different stages, based on the airflow limitation, and 
consequently based on the forced expiratory volume in one second (FEV1) – the 
volume of air exhaled during the first second (GOLD 2017), as shown in table 1.  
 
Table 1 – Classification of severity of airflow limitation in COPD – The 4 stages of COPD, based on 
FEV1. In patients with (FEV1/FVC <70%). 
GOLD 1 Mild COPD, FEV1 ≥ 80% of normal  
GOLD 2 Moderate COPD, 80% > FEV1 ≥ 50% of normal 
GOLD 3 Severe COPD, 50% > FEV1 ≥ 30% of normal 
GOLD 4 Very severe COPD, FEV1 < 30% of normal 
 
Even though this classification is not clinically accurate, since it does not take 
into account some other characteristics of patients with COPD, such as the risk of 
exacerbation, hospitalization, or health status impairment (GOLD 2017), on the 
microbiome research field, this is still the standard used classification. So in the 
present study we will also use it.    
This disease is one of the most common diseases that affect the lungs and 
causes significant morbidity and mortality. According to the World Health 
Organization (WHO), 251 million people worldwide suffer with COPD, resulting in 
approximately 3 million deaths per year (WHO 2017a), leading to a major public 
health problem (Nazir & Erbland 2009). In addition it is estimated that in 2030 this 
will be the third leading cause of death worldwide (WHO 2017a). 
The major cause of COPD is tobacco smoking, including passive exposure 
(WHO 2007). Nevertheless, non-smokers also develop the disease, and so there 
are other risk factors like outdoor, occupational exposure to air pollution, (including 
organic and inorganic dusts and chemical agents), history of pulmonary 
tuberculosis, asthma and respiratory-tract infections during childhood (Salvi & 
Barnes 2009). There are also genetic risk factors that, together with environmental 
factors, can influence the susceptibility to the disease or even its evolution once 
established. One of the well-studied gene associated with COPD is the matrix 
metalloproteinase 12 gene (MMP12) that has been related to loss of lung function 
and increased susceptibility to COPD in smokers (Hunninghake et al. 2009).  
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COPD is frequently punctuated by acute exacerbations (AECOPD). This is 
an acute event characterized by a worsening of the patient’s respiratory symptoms 
that is beyond normal day-to-day variations and leads to change in the regular 
medication (GOLD 2017). During respiratory exacerbations there is an increased 
hyperinflation and gas trapping, with reduced expiratory flow, thus accounting for 
the increased dyspnea (Parker et al. 2005). Some of the symptoms include an 
increased dyspnea, cough, and increased sputum volume and/or purulence (GOLD 
2017). 
These events can lead to considerable morbidity and mortality (Nazir & 
Erbland 2009). Most of the AECOPD are accompanied by a decrease in lung 
function, that is usually transient but a significant percentage of patients may not 
fully recover leading to a further compromised lung function and a growing decline 
of the patient health status (Nazir & Erbland 2009; Seemungal et al. 2000). Even if 
the recovery was not fully accomplished, a patient which do not have an 
exacerbation for 4 to 6 weeks is clinically considered as being recovered 
(Seemungal et al. 2000). 
These acute events are triggered by bacterial or viral infections (which may 
coexist), environmental pollutants, or unknown factors (GOLD 2017). Most of them 
are triggered by microbes, being the bacteria more frequently implicated the 
Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae and 
Pseudomonas aeruginosa (Parameswaran & Murphy 2009). Although, there are 
also non-bacterial exacerbations, it is usually difficult to distinguish between them 
without a sputum culture. In general, one can say that the bacterial exacerbations 
are more severe than the non-bacterial ones (Sethi et al. 2008).  
To treat the exacerbations the most commonly used medication consists of 
bronchodilators, corticosteroids, and antibiotics, such as azithromycin and 
erythromycin (GOLD 2017). However, the use of antibiotics is still controversial 
(GOLD 2017; Miravitlles & Anzueto 2017). Since several studies suggested that the 
treatment with antibiotics has no effect in some patients, and therefore the 
antibiotics side effects, i.e. costs and multi-resistance, should be avoided 
(Vollenweider et al. 2012).   
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According to the WHO, a good management of COPD passes through the 
ability to monitor disease, reduce risk factors, manage stable patients with COPD, 
and mitigate exacerbation events (WHO 2017b). Although current models to predict 
these acute events are based on combinations of information about patient history, 
clinical characteristics, and test results that include biomarkers (e.g. eosinophil 
counts (Pascoe et al. 2015) and C-reactive protein levels in blood (Peng et al. 
2013)). Nevertheless, none of the existing models accomplish the criteria to being 
used in clinic (Guerra et al. 2017; GOLD 2017).   Due to this and since exacerbations 
increase the decline in lung function, deterioration in health status, hospitalization, 
and risk of death (GOLD 2017), it would be pivotal to find a model that could be a 
good predictor of these acute events.  
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1.4 Microbiome and COPD 
 
Lung microbiome has been studied based on culture-dependent methods 
although, these methods underrepresent the diversity of the microbial community 
within a sample (Park et al. 2014). As previously explained, this field had its highest 
development with the emergence of molecular culture-independent methods 
(Huang et al. 2017). Therefore, the last 5 years contributed the most of our 
knowledge in this field, leading to an increased understanding of the roles of 
microbial communities in health and disease, including COPD (Huang et al. 2017). 
It is thought that lung colonization by particular bacterial strains, in patients 
with COPD, is responsible for the chronic bronchitis phenotype, increased risk of 
exacerbations, and loss of lung function, which makes microbiome a potential 
important tool to access COPD progression (Han et al. 2012). 
There are some studies addressing the importance of the microbiome, 
especially the lung microbiome, for the development and worsening of the disease 
state. Some focus on comparing the microbiome of healthy subjects to patients with 
COPD (Sze et al. 2015; Park et al. 2014; Sze et al. 2012). Others focus on temporal 
microbial changes that are observed longitudinally over the course of the disease, 
as, for example, the differences between the microbiome during the exacerbation 
and how it evolves after an AECOPD (Wang et al. 2016; Su et al. 2015; Huang et 
al. 2014).  
 
1.4.1 Microbiome of healthy subjects vs patients with COPD 
Microbiome of patients with COPD has been found to be less diverse than 
from healthy people (Sze et al. 2015; Sze et al. 2012). The abundance of 
Proteobacteria and Bacteroidetes, in lung and oropharyngeal samples of patients 
with COPD, has been comparable with those from nonsmokers and healthy 
smokers but there is an increase of Firmicutes when compared with controls, 
especially in a more advanced stage of the disease (Park et al. 2014; Sze et al. 
2012). In sum, these studies suggest that the lung microbiome of patients with 
COPD is different from that of healthy people, although the microbial diversity varies 
based on sample location and type. Additionally, there are other host factors that 
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are thought to change the microbiome, such as age, medication and disease 
severity, which have to be taken into consideration (Huang et al. 2017).  
 
1.4.2 Microbiome in AECOPD 
The role of bacteria in AECOPD requires a special attention because these 
acute crises are the main cause of morbidity and mortality in patients with COPD 
(Nazir & Erbland 2009). Due to that, it has been largely studied and it is believed 
that bacteria play an important role in the etiology of an exacerbation (Huang et al. 
2017).  
Through culture-based methods from the airways of patients with COPD, 
some authors have demonstrated that exacerbations are associated with pathogens 
such as Streptococcus pneumoniae, Haemophilus influenza, Moraxella catarrhalis, 
Pseudomonas aeruginosa, and Staphylococcus aureus (Soler et al. 2007; 
Hirschmann 2000). On the other hand, since the advent of culture-independent 
methods, several studies  highlighted a higher respiratory microbial complexity 
during these acute events (Liu et al. 2017; Wang et al. 2016; Millares et al. 2015; 
Su et al. 2015; Huang et al. 2014; Millares et al. 2014; Huang et al. 2010). A table 
summarizing this literature findings can be consulted at Appendix 2. 
Huang and colleagues analyzed, through 16S rRNA PhyloChip microarray, 
endotracheal aspirate samples of 8 patients at exacerbation. They identified a core 
of 75 bacterial taxa present in all samples collected during an acute event of the 
disease. Additionally, from these some of them, like Brevundimonas diminuta, 
Arcobacter cryaerphilus and Leptospira interrogans, had never been associated 
with exacerbation before (Huang et al. 2010).  
Millares et al. analyzed, through pyrosequencing of the 16S rRNA, of sputum 
samples from patients with COPD at the baseline and during exacerbation have 
shown that during exacerbation bacteria typically associated with these events, such 
as Streptococcus, Haemophilus, Pseudomonas, Neisseria and Moraxella, were 
increased in relative abundance (Millares et al. 2014). Huang and colleagues 
examined the 16S rRNA gene, using PhyloChip, of sputum samples, before and 
during an exacerbation and also found that there was an increase of the 
Proteobacteria phylum during exacerbation (Huang et al. 2014).  Also Wang et al. 
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found an increased proportion of Proteobacteria, with a decrease of microbial 
diversity during exacerbation, when compared with stable states. They also found a 
proliferation of M. catarrhalis in some individuals, which has been associated with 
increased airway inflammation during AECOPD (Wang et al. 2016; Parameswaran 
et al. 2009). These results suggest that even though there is an overall alteration in 
microbiome during an exacerbation,  there are some individuals that appear to be 
more susceptible to shifts during this period than others (Wang et al. 2016).  
Finally, the microbiome as a whole may not be significantly modified by an 
exacerbation in patients with COPD, as shown by Millares and colleagues (2015). 
When compared with stable state most of the bacteria do not suffer significant 
changes in their relative abundances during an AECOPD (Millares et al. 2015). 
In addition to the studies that compared the microbiome before and during 
exacerbation, there are also some that focus on the microbial shifts after an 
AECOPD. When comparing the microbiome composition during and after an 
exacerbation, Liu et al. (2017), found, in oropharyngeal and sputum samples, 
increased levels of Psychrobacter, Lactobacillus, Rothia, Prevotella, Neisseria, 
Streptococcus, Haemophilus, Actinomyces, Leptotrichia, and Aspergillus, at this 
acute event of the disease.  
 Some authors have found that after treatment there is a major microbiome 
shift, and this shift may be influenced by the treatment prescribed (Wang et al. 2016; 
Huang et al. 2014). This topic will be more deeply analyzed in the next section.  
When comparing samples collected at exacerbation and 7 to 16 days post-
exacerbation, Su et al. (2015), concluded that despite some common variations in 
some phyla such as Firmicutes, Proteobacteria and Fusobacteria, the greater 
variation was found between patients, contributing to patterns almost always 
personalized to each patient. 
Additionally, two different types of AECOPD have been described, the 
“bacterial” and the “eosinophilic” exacerbation. Bacterial exacerbations are 
characterized by the presence of bacterial pathogens in the sample, frequently 
sputum, accessed by a culture, while eosinophilic exacerbations are characterized 
by the presence of more than 3% of non-squamous cells in the sample (Bafadhel et 
al. 2011). 
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 When Wang and colleagues studied the “bacterial exacerbation”, they found 
an increase in Proteobacteria, where in the eosinophilic there was an increase in 
Firmicutes (Wang et al. 2016). Both phenotypes also responded in different ways to 
treatment, i.e. the bacterial phenotype responds better to antibiotics, while the 
eosinophilic responds better to corticosteroids (Gomez & Chanez 2016).  
All these results suggest that there is a significant heterogeneity among 
patients with COPD not just on the microbial diversity during an AECOPD (Su et al. 
2015) but also on the changes of the microbiome composition during the stable state 
versus the exacerbation, and during exacerbation versus after treatment (Wang et 
al. 2016; Su et al. 2015; Huang et al. 2014). 
 
1.4.3 Microbiome after therapy 
The use of different drugs on patients with COPD also interferes with the 
composition of the lung microbiome (Gomez & Chanez 2016).   
Huang and colleagues, (2014), and later Wang et al., (2016), showed that the 
sputum microbiome evolves differently after an exacerbation depending on the 
therapy prescribed. Treatment with antibiotics reduces the abundance of certain 
bacteria, mainly Proteobacteria, while treatment with only corticosteroids leads to 
an enrichment of these bacteria, as well as Bacteroidetes and Firmicutes members, 
while induces a decrease in diversity (Wang et al. 2016; Huang et al. 2014).  It can 
be speculated that the treatment prescribed could, over months or years, lead to an 
alteration in the airway microbiome composition of the patient, that can contribute 
to a raise in the frequency of exacerbations and a worsening of the disease (Huang 
et al. 2017).  
A study conducted by Slater and colleagues, in 5 patients with moderate-to-
severe asthma, on the effects of therapy with azithromycin, demonstrated that 
therapy with this antibiotic was associated with decreased bacterial richness and 
altered airway microbiota, as well as a reduction in the amount of Pseudomonas, 
Haemophilus and Staphylococcus (the three more frequent genera associated with 
airway disease). Further studies must be conducted to confirm these results (Slater 
et al. 2014), along with studies comprehending patients with COPD. 
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1.4.4 The potential role of oral microbiome in COPD 
The role of the oral microbiome in pathologies such as COPD is still poorly 
understood, although it is known that the oral cavity is an important reservoir for 
pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, and some 
Enterobacteriaceae (Amaral et al. 2009). Pragman and colleagues suggested that 
the lung microbiome appears to reflect microaspiration of oral flora in individuals 
with moderate and severe COPD suggesting that the lung microbiome is strongly 
influenced by the oral microbiota  (Pragman et al. 2012). These results are in 
accordance with those from healthy individuals (Bassis et al. 2015; Morris et al. 
2013; Charlson et al. 2011).  
  P. aeruginosa has been detected in both saliva and sputum samples from 
patients with cystic fibrosis. Furthermore, the clone was the same in both samples, 
suggesting an ascending or descending passage of bacteria between the oral cavity 
and lungs (Caldas et al. 2015).  
 Although there is still a lack of studies comprehending the saliva microbiome 
and its association with systemic diseases, there are already some studies that 
confirm that alterations in the salivary microbiome are inherent to some oral and 
non-oral diseases (Acharya et al. 2017). Adding this to what was mentioned above, 
further studies evaluating the role of saliva microbiome in COPD must be conducted. 
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1.5 Aims of the study 
 
In general, the studies presented above show very heterogeneous results 
suggesting that, despite the fact that this field had a great development in the past 
years, there is still much to be clarified (Park et al. 2014), and new hypothesis to 
test. For example, one needs to clarify the true utility of using saliva as a possible 
biomarker source for monitoring patients with COPD, disease status and 
progression. Since 1) saliva is one of the most easily collectable human fluid, 2) it 
has been used in the past to detect non-respiratory pathologies, and 3) has been 
shown to be a reservoir of bacteria traditionally associated with lung microbiome, it 
seems a very promising vehicle for COPD-related information. 
This Master thesis aims to contribute to this effort, by implementing the 
methodology to study the saliva microbiome in patients suffering from Chronic 
Obstructive Pulmonary Disease, as a way to understand the dynamics of saliva 
microbiome in the setting of an exacerbation and how the microbiome evolve after 
that.  
The specific objectives were: 
 To carry out a literature survey that would allow to establish major 
microbiome features to focus in the subsequent study; 
 To establish protocols for the saliva collection, conservation, transport 
and laboratorial treatment to reach good overall sample quality; 
 To characterize the saliva microbiome of 7 different patients with COPD, 
using a culture-independent method, based on NGS sequencing of 16S 
rRNA gene amplicons and bioinformatics analyses; 
 To study the microbiome shifts on a total of 17 samples, that were 
collected in different time points of the disease, i.e., at the exacerbation 
onset, two weeks after the exacerbation, and after full clinical recovery (6 
weeks and 8 months after exacerbation); 
 To conclude, based in the results, if the overall methodology is able to 
detect microbiome fluctuations relevant for COPD management, to be 
used in future larger projects. 
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2.1 Subjects and sample collection 
  
All the samples were collected from male patients with COPD, which have 
been enrolled under the scope of “Genial – Marcadores Genéticos e Clinicos na 
Trajectória da DPOC”, funded by Programa Operacional de Competitividade e 
Internacionalização - COMPETE, through Fundo Europeu de Desenvolvimento 
Regional - FEDER (POCI-01-0145-FEDER-016701), Fundação para a Ciência e 
Tecnologia (PTDC/DTPPIC/2284/2014) and under the project 
UID/BIM/04501/2013. 
Individuals were classified into four distinct stages according to the GOLD 
guidelines (GOLD 2017). All participants were informed about all stages and 
conditions of the experiment before they gave their written informed consent, 
(Appendix 3). 
We took advantage of this cohort, since it has been clinically characterized. 
All the characteristics, including lung function, as well as muscular and functional 
tests and patient reported outcomes, can be found in Appendix 4. 
Sociodemographic and clinical data were collected, including smoking habits, 
medical antecedents, and treatments (table 2). Participants’ lung function was 
accessed following the guidelines. Forced Expirometry Volume in 1 second (FEV1) 
was registered, as shown in table 2.  
 
Table 2 Clinical characteristics of patients* 
Subject Age 
(yr) 
FEV1 
(%) 
GOLD Smoking status (pack-
yr) 
Treatment for 
Exacerbation 
519 75 61 1 Former (30) Azithromycin 
526 78 31 3 Former (108) Methylprednisolone 
555 76 56 2 Former (60) Levofloxacin 
S29 58 18     4 Former (60) Azithromycin 
E44 73 60 2 Never smoke None 
587 77 84 1 Former (1) None 
616 54 44 3 Former (38) Azithromycin 
*All subjects were male. Age, lung function, GOLD classification and smoking status were collected during the time of 
enrollment in this study; FEV1, forced expirometry volume in 1s; pack-yr, number of packs of cigarettes smoked per day 
multiplied by the number of years that the person has smoked. 
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17 saliva samples were collected for microbiome assessment from 7 different 
individuals, at different time points. Samples were collected during exacerbation, 
before the administration of antibiotic therapy, 2 weeks post-therapy and/or at 
clinical recovery (6 weeks – recovery, and 8 months after exacerbation – 
recovery_B), as depicted in table 3. The time points of sample collection were 
chosen based on the fact that after 4 to 6 weeks of an exacerbation a patient is 
clinically considered to be fully recovered (Woodhead et al. 2011). For some 
patients, it was also possible to obtain samples collected after 2 weeks of 
exacerbation. These samples would allow us to deeply characterize the microbial 
changes after an exacerbation and subsequent treatment. For one patient (subject 
526), it was also possible to collect a sample 8 months after the exacerbation, which 
would allow to compare the microbiome composition in two different time points of 
clinical recovery. 
 
Table 3 – Time points of sample collection per subject, at exacerbation, 2 weeks after 
exacerbation, 6 weeks after exacerbation ”Recovery” and 8 months after exacerbation 
“Recovery_B”  
Subject Exacerbation Post 2 weeks Recovery Recovery_B 
519 X X X  
587 X X X  
526 X  X X 
555 X X   
E44 X  X  
616 X  X  
S29 X  X  
 
 
During sample collection, subjects were asked to spit into sterile falcons 
(F50). Specific precautions were taken during this procedure to avoid contamination 
of the samples, as described in (Goode et al. 2014). All subjects were advised to 
avoid ingestion of any acidic substances, aliments rich in sugar or in caffeine, at 
least one hour before data collection since these can cause changes in the saliva 
pH and lead to changes in bacterial composition (Zaura et al. 2017). Patients were 
also advised to mouthwash with water 10 minutes before the sample collection to 
minimize the presence of food particles and any modification in saliva pH. Once 
finished the collection, the falcons were properly labelled, transported in portable 
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freezers to the Institute for Research in Biomedicine (iBiMED) where they were 
preserved in freezers at -80ºC, until further processing, which occurred within 8 
months interval. 
 
2.2 DNA Extraction and Quantification 
  
Bacterial DNA was extracted from saliva samples using the QIAamp DNA 
Microbiome kit (QIAGEN, Valencia, CA, USA) according to the manufacture’s 
protocol – Depletion of host DNA (QIAGEN® 2014) 
First, host cells were lysed by incubation with Buffer AHL, followed by a 
centrifugation, which separated the bacterial cells from the host cellular debris 
(including human nucleic acids). After that, an incubation with Benzonase and 
Proteinase K degraded the remaining human nucleic acids, avoiding them to be 
major contaminants of the bacterial DNA extract. Then, efficient lysis of Gram-
negative and Gram-positive bacteria was assured, due to an incubation with 
detergent-containing buffer ATL and a further step of bead-beating. Afterwards the 
bacterial DNA was purified through adsorption to silica membranes present in 
columns from the Qiagen kit. DNA-containing silica membranes were washed with 
two washing buffers to ensure complete removal of residual contaminants. Purified 
bacterial DNA was eluted, and was ready for subsequent handling.    
Before starting all the extractions, several tests were done to optimize the 
protocol, so that DNA extraction yield amounts were above 50 ng/μl (as given by 
DeNovix DS-11 FX+ quantification). From these preliminary testing the following 
modifications resulted: 
 Due to the limited quantity of saliva collected (4 of the 17 samples did not 
have 1 ml of saliva),  the protocol was then adapted to process 500 µl of 
sample, by adjusting the volume of Buffer AHL to the half, as suggested by 
the kit protocol. A table including all the sample volumes can be found in 
Appendix 5. 
 Instead of an incubation of 30 minutes of the Buffer AHL, samples were 
incubated for 1 hour, to assure a more efficient lysis of host cells. 
32 
 
 For lysing bacterial cells, a Mixer Mill MM 400 by Retsch® was used. We 
applied a frequency of 30 Hz for 5 minutes, followed by 5 minutes in ice, and 
another step of 5 minutes at 30 Hz, based on the protocol described by 
Yamagishi et al. (2016).  
 At the drying step, instead of a centrifugation at 20000 x g for 1 minute, we 
performed a centrifugation for 2 minutes. This step aims to dry off the 
membrane before eluting the DNA. By raising the duration of the 
centrifugation, one decreases the chance of ethanol contamination.  
 All samples were eluted using Milli-Q water, since no prolonged storing was 
predicted for these samples.   
DNA was quantified using the DeNovix DS-11 FX+ - a spectrophotometric 
method. Due to the literature-reported frequent overestimation of DNA quantity that 
is given by a spectrophotometric method (Simbolo et al. 2013), we also used a 
fluorometric method - Qubit® dsDNA HS Assay Kits. Only samples with a DNA yield 
> 10 ng/μl, given by Qubit were used for subsequent analysis. Only one sample was 
below this threshold and it was left from sequencing, due to the impossibility of doing 
additional extractions since that sample had a limited quantity of saliva. A table 
including all the samples from which DNA was extracted and the correspondent 
concentration can be found in Appendix 5.  
Eluted DNA was then stored at -20ºC until further analysis, which happened 
within 45 days.   
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2.3 PCR amplification and amplicon sequencing 
  
PCR amplification, library building and fragment sequencing was performed 
at Instituto Gulbenkian de Ciência (IGC), Oeiras, Portugal. The hypervariable V4 of 
the 16S rRNA gene was amplified following the protocol described in Walters et al., 
(2016). The V4 region was amplified with the modified primers 515f (5’ – 
GTGYCAGCMGCCGCGGTAA – 3’) and 806r (5’ – GGACTACNVGGGTWTCTAAT 
– 3’) (Parada et al. 2016; Apprill et al. 2015). These primers are modified versions 
of the original ones proposed by Caporaso et al., (2011), which were found to 
introduce biases against SAR11 clade, and two important environmental Archaea  
(Walters et al. 2016). PCR was performed in a final volume of 25 μl containing 13 μl 
of PCR-grade water, 10 μl of 5’ Hot master mix, 0,5 μl of forward primer (10 μM), 
1,0 μl of reverse primer (10 μM), and 1,0 μl of template DNA. The following PCR 
conditions were used: initial denaturation for 3 min at 94ºC; followed by 35 cycles of 
45 sec at 94ºC, 60 sec at 50ºC, and 90 sec at 72ºC; with a final extension of 10 min 
at 72ºC, and finally a 4ºC hold.  
 Amplicons were then used to build Illumina libraries and sequenced using 
Illumina MiSeq System, as described in the manufacture’s protocols, Illumina 
(2015). The sequencer uses a reversible terminator sequencing by synthesis (SBS) 
approach -  using four fluorescently labelled nucleotides in a massive parallel 
environment (Illumina 2015b). The overview of this process is synthetized in figure 
4. Briefly, 
 The protocol started with a library preparation, where specific adapters 
were added to the 3’ and 5’ ends (Hodkinson & Grice 2015; Illumina 
2015a) (figure 4a). 
 The library was then loaded into a flow cell where fragments were 
captured. Once attached to the flow cell, the single stranded DNA 
fragments underwent bridge amplification, resulting in a cluster of 
identical fragments (Lu et al. 2016; Illumina 2015a; McElhoe et al. 2014). 
When cluster generation finished, the templates were ready for 
sequencing (figure 4b). 
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 During each sequencing cycle, labelled deoxynucleoside triphosphate 
(dNTP) was automatically added to the nucleic chain. The label works as 
a terminator for polymerization, so after each dNTP incorporation, the 
fluorescent dye can be imaged to identify the base and then cleaved to 
allow the incorporation of the next nucleotide (Illumina 2015a). Since each 
incorporated base is accessed separately, the sequencing errors are 
significantly reduced (McElhoe et al. 2014) (figure 4c). 
The final outputs of the sequencing platform were fastq format files which 
were then used for bioinformatics sequence analysis (Hodkinson & Grice 2015). The 
fastq format comprehends the nucleotide sequencing with its corresponding quality 
scores (Deorowicz & Grabowski 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. b. 
c. 
Figure 4 - MiSeq Illumina sequencing workflow – a. Library preparation, b. Cluster amplification, 
and c. Sequencing, from Lu et al. (2016). 
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2.4 Sequence analysis  
  
The primary sequence analysis was also performed at IGC.  These analyses 
were done with Quantitative Insights Into Microbial Ecology 1.9.1 (QIIME 1.9.1) (J. 
Gregory Caporaso et al. 2010), an open source pipeline that can perform standard 
microbial community analysis, starting with raw sequence data and using statistical 
analysis and visualization steps (Navas-Molina et al. 2013; Caporaso et al. 2011).  
 QIIME analysis started with fastq files and a user-generated mapping file, 
which contained all required information about each sample. This included the 
sample ID, the state (exacerbation, post 2 week, and recovery – 6 weeks and 8 
months after exacerbation) at which the patient was at the time of sample collection, 
the usage or not of antibiotics for treating the exacerbation, the amount of saliva 
collected, and amount of DNA extracted.   
The analysis required some preprocessing steps. The first was the 
demultiplexing step which consists of removing all barcodes and primer sequences 
and assigning reads to each sample, so that only the sequences matching the 
amplified 16S rRNA gene for each sample remain (Navas-Molina et al. 2013). 
Default parameters were applied to this step. 
The quality-filtering performed next removed the sequence reads that did not 
reach a minimal quality score. Like most sequencing instruments, Illumina 
instruments generate a quality score for each nucleotide (Phred scale, (Ewing et al. 
1998)), related to the probability of incorrect base calling. To filter reads by quality, 
QIIME uses Phred score and user-defined parameters, in this case default 
parameters were used, which were r = 3, p = 75%, q = 3, and n = 0 (r – the maximum 
number of consecutive low-quality base calls; p – the percentage of consecutive 
high-quality base calls; q – the minimum Phred quality score; n – the maximum 
number of ambiguous bases) (Bokulich et al. 2013). 
 The next part of the QIIME pipeline was clustering the sequence of reads into 
OTUs. Sequences were clustered together according to a threshold of sequence 
similarity, set at 97%. This value has been conventionally assumed to separate 
bacterial species, when using 16S rRNA sequencing (Drancourt et al. 2000). QIIME 
supports three approaches for OTU picking (de novo, closed-reference, and open-
reference). The de novo approach clusters sequences based on sequence identity, 
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the closed-reference matches sequences to a database of reference sequences, 
while the open reference approach combines the de novo and the closed-reference 
approach (Navas-Molina et al. 2013). 
Our collaborators at IGC used the open-reference approach. It started with 
the sequences being compared directly with a reference sequence collection (in this 
case GreenGenes v13_8 database), as with the closed-reference approach, but 
then, the sequences which had no hit were clustered into OTUs by the de novo 
method - sequences were compared to each other and then clusters were formed 
(Navas-Molina et al. 2013). The algorithms used for the OTU picking method were, 
blast, for the closed reference (Altschul et al. 1990) and uclust (Edgar 2010), for the 
de novo approach. 
 The next step was to assign the taxonomy to each sequence of the 
representative set, in other words, this step connected the OTUs to named 
organisms. Due to the use of a partial de novo approach, some clusters were not 
named according to any reference database, and so, in those cases, the taxonomy 
must be assigned using a reference dataset (Navas-Molina et al. 2013). In this study 
GreenGenes (v13.8) database was used. To assign taxonomy against the 
database, uclust was used.  
 The sequence alignment, needed for this step was performed by PyNAST 
(Caporaso et al., 2010) using as reference the GreenGenes core set (DeSantis & 
Hugenholtz 2006) as explained.   
The construction of a phylogenetic tree was the next step after assigning to 
each cluster the right taxonomical identity. The output was the taxa that were 
present in each sample, which can be used for diversity analyses and to understand 
the relationship among the sequences in a single sample. For that, FastTree was 
used (Price et al. 2009). 
 Finally, the last step of this pipeline was the construction of the OTU table. 
The OTU table is a matrix that shows the abundance of each OTU in each sample, 
and includes also the taxonomic prediction for each OTU. The output was a compact 
file in Biological Observation Matrix (BIOM) format (Mcdonald et al. 2012).  
 The workflow about the sequence analysis done in this study is summarized 
in figure 5. 
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Figure 5 - QIIME workflow overview. This analysis starts with preprocessing the sequencing reads and 
ends with the OTU table and the phylogenetic tree (output).  The white box represents the required 
input files, while the grey ones represent the output files given by QIIME. The grey and white boxes, 
show the different steps (in grey), and the methods used for each step (in white) (Adapted from: 
Navas-Molina et al., 2013). 
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2.5 Statistical analysis and visualization 
  
Before any analyses, sample depth had to be determined, since it defines the 
size of the random subset of sequences that were selected for each sample for all 
subsequent analyses (Navas-Molina et al. 2013). Based on our data, the reasonable 
rarefaction level was 10342 sequences per sample, which was the number of 
sequences found in the sample that had less sequences. This normalization step is 
important because most of the diversity analyses used are very sensitive to the 
number of sequences used by sample, which has to be homogenized (Kuczynski et 
al. 2012). 
For an overview analysis of the family and genus taxa a phylogenetic tree 
was created using the webtool phyloT (Letunic 2015). PhyloT uses the NCBI 
taxonomy database to generate a phylogenetic tree based on a list of taxa given by 
the user. 
To study the diversity of a microbial community, one can look at the alpha, 
and beta-diversities. Alpha diversity is defined as the diversity of organisms in one 
sample or group of samples, on the other hand, beta-diversity studies the difference 
in diversities across samples, or groups of samples (Navas-Molina et al. 2013). 
When studying the alpha-diversity, we were interested in estimating the 
community richness i.e. the number of different OTU’s within a sample; as well as 
the community diversity, which englobes the number of OTU’s and how these OTU’s 
are distributed (evenness) (Morgan & Huttenhower 2012). 
To study the alpha-diversity, we used the observed number of OTUs and the 
Chao1 estimator (Chao 1984) – the Chao1 estimator is a metric that predicts the 
total number of OTU’s that would be seen with an infinite number of samples. To 
study the community diversity, we used the Shannon  (Shannon & Weaver 1963) 
and Simpson indexes (Simpson 1949), which are robust estimators of diversity 
(Haegeman et al. 2013).  Simpson index measures the probability of two individuals 
arbitrarily selected from a sample to belong to the same species, while Shannon 
index is an entropy measurement which increases with the number of species in the 
sample (Escobar-Zepeda et al. 2015). The difference between the two statistical 
distributions is that the Shannon index values more the rare species in the sample, 
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while Simpson index values more the common species (Krebs 2014). Here, we 
calculated alpha-diversity for 1) each sampling time point (exacerbation, pos2 and 
recovery), 2) each patient (samples grouped by patient) and 3) each sample 
collected per patient.  
To access the beta-diversity, the first Bray-Curtis dissimilarity  metric (Bray & 
Curtis 1957) was used, which quantifies the compositional dissimilarity between the 
groups based on the number of counts per sample. Then to evaluate if these 
dissimilarities were statistically significant, a permutational multivariate analysis of 
variance – PERMANOVA (Anderson 2001) (with 999 permutations) was used. This 
test was used to test the heterogeneity of community structure in a priori groups i.e. 
age, antibiotic treatment, smoker status, sampling time points, patients). 
Other beta-diversity measures were also used, such as the UniFrac 
(Lozupone & Knight 2005), which uses phylogenetic information to compare 
samples. For that, all the taxa found in the samples, were placed on a phylogenetic 
tree, then the amount of unique evolution within each community is measured and 
compared to another, by calculating the fraction of branch length of the phylogenetic 
tree that is unique to either one of the pair of communities (Lozupone & Knight 2005; 
Navas-Molina et al. 2013). We used the unweighted UniFrac, a qualitative measure 
which has provided results that correlate better with clinical variables than weighted 
UniFrac (Navas-Molina et al. 2013). The UniFrac measure can be coupled with 
standard multivariable statistics such as a dendogram (Tyrion 1939) or Principal 
Coordinates Analysis (PCoA) (Mardia et al. 1979). We used unweighted UniFrac 
measure combined with a dendogram (Tyrion 1939) to identify potential clusters of 
samples, as well as a PCoA (Mardia et al. 1979), to  visualize phylogenetical 
dissimilarities between samples. 
All the alpha and beta–diversities measures were performed using the R 
statistical software version 3.4.2 (R Core Team 2015) and the RStudio, version 
1.1.383 (RStudio Team 2016), using the packages vegan (Oksanen et al. 2017) and 
phyloseq (McMurdie & Holmes 2013).  
Considering the results given by the previous tests, STAMP v2.0.0 (Parks et 
al. 2014) was used to analyze the three time points at which samples were collected, 
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and to look for statistically significant shifts in the relative abundance of certain taxa, 
through ANOVA with Games-Howell post hoc testing (Bluman 2007).    
There was also a need to visualize the microbiome shifts over time. Samples 
were grouped by time of collection and plots were built showing the overall taxa 
relative abundance per group of samples. The same was also performed for each 
subject, but instead of grouping the samples, they were displayed as a way to 
compare the different time points of sample collection, and presented as plots 
showing the relative abundances per sample. 
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Chapter III – Results 
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3.1 Participants 
  
For each subject a single sample was obtained at the onset of the 
exacerbation and always before new treatments were started (“Exacerbation”). 
Additionally, one or two samples were collected from the same patient, either “Pos 
2”, taken 2 weeks after the exacerbation date, “Recovery” – after 6 weeks , or 
“Recovery_B” – 8 months after  exacerbation. All patients were male, mean age of 
70,1 years, and most had moderately severe airflow obstruction (GOLD 2 - FEV1 
between 50 and 80% (GOLD 2017)). All, except one that never smoked, were 
former smokers. The medication prescribed, or not, for the treatment of the 
exacerbation, as well as other characteristics were described earlier on Chapter II 
(see table 2 and 3). 
 
 
3.2 Sampling and Sequencing 
  
Bacterial DNA was successfully extracted, amplified and sequenced from 17 
samples of saliva. After the preprocessing steps, a total of 393 826 reads remained. 
Figure 6 - Distribution of sequencing depth – number of reads per number of 
samples. Most of our samples had between 2000 and 3000 read counts. 
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The distribution of reads was between 10 342 and 40 333 per sample, distributed 
as shown in figure 6. 
The bacterial sequences were then normalized to 10 342 randomly chosen 
reads and clustered by OTUs similarity. The number of OTUs observed at 97% 
identity was 3848. During the analysis some of the OTUs were found to be 
“Unassigned” for the Kingdom rank, to avoid further misinterpretations, those OTUs 
with this classification were removed, leading to final count of 3574 OTUs.  
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3.3 Overall microbial community  
 
Among all samples 3574 different OTUs were found, 4 belonging to Archaea 
and 3570 to the Bacteria Kingdom. The later was represented by several species 
belonging to distinct families (n=70) and genera (n=88), as shown in figure 7.  
 
* The genus Pseudoramibacter and BD2-13 strain were also detected in the samples 
although they are not included in this tree, because PhyloT could not recognize them. 
 
 
 From the total amount of genera detected one can deduce a “core 
microbiome”, i.e., a group of taxa that were found in all samples collected. This 
group was formed by Actinobacillus, Akkermansia, Bacteroides, Fusobacterium, 
Gemella,  Haemophilus,  Leptotrichia, Parviromonas, Prevotella, Rothia, 
Figure 7 - Phylogenetic tree showing the overall bacterial diversity at the genera* level that was 
detected in our cohort of saliva samples from patients with COPD. 
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Streptococcus, Veillonella, members of the family Bacteroidales, Lactobacillalles 
and Lachospiraceae, and taxa belonging to the Bacilli class. 
 
Table 4 – Relative abundance presented across all samples, relative to phyla and genera levels. 
Taxa with higher relative abundances are highlighted. Firmicutes and Actinobacteria were the phyla 
detected with higher relative abundances. 
Phyla Genera 
14,3% Actinobacteria 1,4% Actinomyces 
  0,2% Corynebacterium 
  12,3% Rothia 
  0,3% Atopobium 
5,1% Bacteriodetes 0,7% Porphyromonas 
  1,9% Prevotella 
  2,2% Capnocytophaga 
  0,1% Unclassified 
0,2% Cyanobacteria 0,2% Unclassified 
43,7% Firmicutes 0,3% Bacillus 
  3,5% Gemella 
  0,2% Granulicatella 
  0,2% Lactobacillus 
  22,2% Streptococcus 
  0,2% Moryella 
  0,8% Oribacterium 
  0,1% Filifactor 
  0,1% Peptostreptococcus 
  0,1% Daliaster 
  0,2% Megasphaera 
  0,1% Schwartzia 
  0,2% Selenomonas 
  11,5% Veillonella 
  0,1% Mogibacterium 
  0,3% Parvimonas 
  0,3% Bulleidia 
  3,2% Unclassified 
9,1% Fusobacteria 1,6% Fusobacterium 
  7,5% Leptotrichia 
27% Proteobacteria 0,3% Lautropia 
  0,2% Kingella 
  16,1% Neisseria 
  0,3% Campylobacter 
  0,1% Cardiobacterium 
  0,3% Actinobacillus 
  0,6% Aggregatibacter 
  8,8% Haemophilus 
  0,3% Unclassified 
0,1% Spirochaetes 0,1% Treponema 
0,1% Synergistetes 0,1% TG5 
0,4% Unassigned   
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As it can be seen in table 4, the most common phyla detected among samples 
was Firmicutes (43,7%), Proteobacteria (27,0%), Actinobacteria (14,3%), 
Fusobacteria (9,1%), and Bacteroidetes (5,1%). Of the 88 genera identified, the 
most abundant were Streptococcus (22,2%), Neisseria (16,1%), Rothia (12,3%), 
Veillonella (11,5%), Haemophilus (8,8%), and Leptotrichia (7,5%). 
Curiously, even though presented at a higher relative abundance, Neisseria 
was not included as a genus presented at the “core microbiome”, as can be seen in 
figure 8, Neisseria were just present in 16 out of the 17 samples (this genus was 
absent of  the exacebertion sample from patient 616). 
 
 
 
 
 
Figure 8 - Prevalence of the most abundant genera, per total of counts, in all samples (n=17). 
Neisseria had an overall high relative abundance, even though it was absent from one of the 
samples. 
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3.3.1 Alpha-diversity  
Relatively to the observed bacterial richness (number of different OTU’s) 
found in each sample. The number of OTU’s per sample varies between 279 and 
1516 taxa, being the average 887 taxa. Overall one can see that the bacterial 
richness was similar between the samples collected from the same subjects, 
although the bacterial richness among the different times of collection varies, being 
impossible to find a pattern. Nevertheless, there are two samples from all the cohort 
that stand out - the sample collected at exacerbation, from patient 616, that has the 
lowest richness and the sample collected at recovery (6 weeks after exacerbation) 
from patient 519 that has the highest richness from all cohort (figure 9).  
 
 
Figure 9 - Bacterial richness (number of taxa per sample) detected in each patient sample. 
“Exac” – exacerbation; “post2” – 2 weeks after exacerbation, “recovery” – recovery (6 weeks 
after exacerbation), “recovery_b” – recovery (8 months after exacerbation). From the figure, one 
can affirm that the sample from patient 616 collected at exacerbation has the lowest richness, 
while the sample “recovery” from patient 519 has the higher richness from all cohort. 
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3.3.2 Beta-diversity  
To further evaluate the relationship between community composition and 
clinical patient characteristics, Bray-Curtis dissimilarity metric matrices were built 
(Bray & Curtis 1957) and then a permutational multivariate analysis of variance 
(PERMANOVA) was performed (Anderson 2001) in order to identify statistically 
significant dissimilarities in the groups. No significant dissimilarities (p-value > 0.05) 
were found between community composition and parameters such as age 
(PERMANOVA analysis, F = 1.29, R2 = 0.26, p-value = 0,079), the antibiotic 
treatment (PERMANOVA analysis, F = 1.38, R2 = 0.16, p-value = 0.169), regarding 
the smoker status (PERMANOVA analysis, F = 1.18, R2 = 0.073, p-value = 0.313), 
and the GOLD stage (PERMANOVA analysis, F= 1.24, R2= 0.22, p-value= 0.23). 
Additionally, the only factor of variability in all the technical procedure, from DNA 
extraction until data analysis, was the fact that 4 out of the 17 samples analyzed 
had only 500 μL of saliva, so we also test if this originated any dissimilarity between 
the two groups, again with no statistically significant differences (PERMANOVA 
analysis, F = 0.81, R2 = 0.051, p-value = 0.585). 
On the other hand, significant correlations (p-value<0,05) were found 
between the time points at which samples were collected (PERMANOVA analysis, 
F = 1.70, R2 = 0.2813, p-value = 0.043), and among patients (PERMANOVA 
analysis, F = 2.23, R2 = 0.573, p-value = 0.001). These results show that that there 
are significant differences in the community composition of samples when they are 
grouped by time of collection and by patient. 
Furthermore, a cluster dendogram, using the unweighted UniFrac distance 
metric, was conducted (figure 10). This dendogram shows that samples were 
clustered based on the patient from which they were collected. Showing higher 
variability between patients than between disease states. With the exception of 
patient 616 and the “recovery” sample of patient 519. These results show that the 
two samples collected for patient 616 do not have a similar phylogenetic 
composition, as well as the “recovery” sample from patient 519 does not have a 
similar phylogenetic composition when compared with the other two samples 
collected from this patient.  
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 Additionally, an unweighted UniFrac coupled with Principal Coordinate 
analysis (PCoA) was performed to validate the previous results (figure 11). The 
cohort was composed by a very small number of samples (n=17), so changes in the 
community structure between samples at different time points were not observed. 
With exception of the fact that the sample collected 8 months after exacerbation 
(Recovery_B) from the patient 526, and the sample collected at recovery from 
patient 616, appear to have a community structure more different from the other 
samples collected. 
 
 
 
 
 
Figure 10 - Cluster dendogram with unweighted UniFrac distance metric of all samples 
collected. “exac” – exacerbation; “pos2” – two weeks after exacerbation; “recovery – 6 weeks 
after exacerbation; “recovery_B” – 8 months after exacerbation”. Note that samples became 
clustered by patient, showing higher variability between patients than between disease states 
for the same patient. 
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Figure 11 - Principal cordinate analysis (PCoA) showing the distribution per time of sample 
collection (Exac – exacerbation, Pos2 - after two weeks of exacerbation, Recovery – after 6 
weeks of exacerbation, and Recovery_B – 8 months after exacerbation). Note that there is no 
degree of separation, whith exception for the sample collected at “Recovery_B” and one of the 
samples at “Recovery”. 
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3.4 Microbiome over time points 
 
Given the results shown above, alpha-diversity was studied in groups of 
samples collected at the same time points, measured through richness (number of 
OTU’s observed and Chao1), and diversity (Shannon and Simpson) as shown in 
figure 12. When comparing alpha-diversity, our results indicated an overall increase 
in richness and diversity in the samples collected after 2 weeks of exacerbation, 
contrary to exacerbation and recovery (6 weeks and 8 months after exacerbation). 
Interestingly, alpha-diversity at AECOPD and recovery was remarkably similar. 
Figure 12 - Alpha diversity comparitions between time points (Exac – exacerbation; Pos2 – two 
weeks after exacerbation; Recovery – 6 weeks; Recovery_B - 8 months after exacerbation). 
Samples were agroupped by the time of collection, and bacterial richness (Observed, and 
Chao1) and diversity (Shannon and Simpson Index) were calculated. All indexes are increased 
at the middle time point, i.e. two weeks after exacerbarion, when compared to the other three 
sampling times. 
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Note that when comparing the bacterial diversity at exacerbation and at 
recovery, depending on the index used the results are different. For the Shannon 
index, which values more the rare species within the community (figure 12), one can 
see that the group of samples collected at exacerbation had more rare species that 
the samples collected at recovery. 
Looking now at the taxonomical composition of samples, at exacerbation, the 
most common phylum was Firmicutes, followed by Proteobacteria, Actinobacteria, 
Fusobacteria and Bacteroidetes (see Appendix 6). At genera level, the most 
abundant genera were Streptococcus, Neisseria, Rothia, Veillonella, and 
Haemophilus (figure 13). 
 
 
Figure 13 - Samples have been grouped and averaged by time of collection – exacerbation 
(Exac), 2 weeks after exacerbation (pos2), and 6 weeks (Recovery) and the sample collected 8 
months post exacerbation (Recovery_B) -, and taxonomic composition is shown at the genera 
level. Each column in the plot represents a time of sample collection, and each color in the 
column represents the relative abundance of the total sample contributed by each taxon group 
at genera level. The relative abundance of Streptococcus is decreasing over the time. The 
taxonomical composition of “Recovery_B” is remarkably different from the samples collected at 
“Recovery”. 
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From figure 13, one can see that there was a decrease in abundance of the 
genus Streptococcus over time, and the taxonomical composition of the samples 
collected at “recovery” (after 6 weeks of exacerbation) and at ”recovery_B” (8 
months after exacerbation) are remarkably different. Since the “recovery_B” group 
was just composed of one sample, caution must be taken when extrapolating 
results. This topic will be further discussed when comparing the samples collected 
from subject 526. 
In order to compare differences in the relative abundances at different time 
points we used ANOVA with the Games-Howel post-hoc test, to test if there were 
differences (p < 0,05) in the relative abundances of the most abundant taxa, at phyla 
and genera level. When comparing the three collection time points (we grouped 
all the samples collected at recovery, i.e “recovery” and “recovery_B”). There were 
no significantly differences in the relative abundances at phyla level. However, at 
genera level there was a decrease in the relative abundance of Streptococcus (p-
value = 0.029, ANOVA with Games-Howel post- hoc test). There was also a 
significant shift in the relative abundance of Rothia, with an increase of this genus 
at the samples collected after 2 weeks (p-value = 0.047, ANOVA with Games-Howel 
post- hoc test). The same trend was observed for Oribacterium (p-value = 0.024, 
ANOVA with Games-Howel post- hoc test) (see appendix 7). 
 When pairwise comparisons were conducted, at phyla level, there was a 
significant increase of Fusobacteria at “pos2”, when comparing with the samples 
collected at exacerbation (t-test, p-value = 5.02e-3), while there was a significant 
decrease of Actinobacteria in “recovery” comparatively to “pos2” (t-test, p-value = 
0.027) (see appendix 8). No statistically significant differences were found at the 
level of relative abundance, at phyla level, between samples collected at 
exacerbation and samples collected at recovery.    
At the genera level, there was a significant increase of Oribacterium at “pos2” 
when comparing with “exacerbation” (t-test, p-value = 0.021) as well as an increase 
in Leptotrichia for the same time points (t-test, p-value = 0.011). Additionally, when 
comparing the exacerbation samples with the samples collected at recovery, there 
was a significantly decrease of the genus Streptococcus (t-test, p-value = 0.018), 
as would be expected by the results from the ANOVA. However, the highest 
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differences, in terms of relative abundance, were found between the samples 
collected at “pos2” and at “recovery”, where there were significant decreases of 
Rothia (t-test, p-value = 2.02e-3), Oribacterium (t-test, p-value = 0.032), and 
Veillonella (t-test, p-value = 0.034), while there was a significant increase in the 
relative abundance of Neisseria (t-test, p-value = 0.049) (see appendix 9). 
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3.5 Microbial composition of individual subjects 
 
Changes in the microbial community of different patients during the time 
course were explored, based on the results of the PERMANOVA with the Bray-
Curtis metric. For that, samples were grouped by patient and alpha-diversity for 
each patient was accessed, through richness (number of OTU’s observed and 
Chao1 estimator) and diversity (Shannon and Simpson index), as shown in figure 
14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From figure 14, it became clear that samples collected from patient 587 had 
higher richness, while samples from patient 519 had higher diversity. On the other 
hand, patient 616 presented the lowest richness and diversity. 
Figure 14 - Alpha diversity comparisons between patients. Samples were groupped by patient 
clustering all the samples collected at different time points , and bacterial richness (Observed, 
and Chao1), diversity (Shannon and Simpson Index) were calculated. Samples from patient 587 
had the higher richness, while samples from patient 519 had higher diversity. The samples 
collected from patient 616 had the lowest richness and diversity. 
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 Given these results, that show that there was a great inter-subject variation, 
it became important to analyze every patient individually.   
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3.5.1 Subject 519 
Subject 519 was a 79 years old man with moderate COPD (GOLD stage 2)  
that was recruited during exacerbation and treated with azithromycin, a large 
spectrum antibiotic often used for AECOPD treatment (GOLD 2017). Three samples 
were collected from this subject, exacerbation (“Exacerbation”), after 2 weeks 
(“Pos2”) and after 6 weeks (“Recovery”) of exacerbation.  
Firmicutes, Actinobacteria, and Proteobacteria were the most abundant 
phyla. As a curiosity, at exacerbation and before any treatment, a bacteria of the 
Cyanobacteria phylum was identified (Appendix 6), across the three samples 
collected from this patient. On the other hand, Streptococcus, Veillonella, and Rothia 
were the genera with highest relative abundance (figure 15).  
For this patient, “Recovery” was the time point of highest diversity, while the 
sample collected at exacerbation showed the lowest diversity, as can be seen in 
table 5.  
 
Table 5 – Bacterial richness (number of OTU’s observed and Chao1 estimator) and diversity 
(Shannon and Simpson indexes) of the samples collected from patient 519. “Exacerbation” – 
exacerbation, “Pos2” – 2 weeks after exacerbation, “Recovery” – 6 weeks after exacerbation. 
 Richness Diversity 
 Observed Chao1 Shannon Simpson 
519 – Exacerbation 830 1357.58 3.47 0.88 
519 – Pos2 1030 1991.57 3.99 0.94 
519 - Recovery 1516 2061.63 4.41 0.95 
 
 
When comparing the relative abundances, at genera level, of the three 
collecting points, some patterns could be highlighted, such as the relative 
abundance of Streptococcus and Rothia that decreased over time, while the relative 
abundance of Veillonella, Leptotrichia, Prevotella, and Neisseria increased over 
time, even though the last one shows a really small increase at recovery, when 
comparing with “Pos2”.  
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Curiously, Haemophilus was increased at “Pos2”, when comparing with the 
other two collecting points, whereas the genus Lautropia were only present at 
“Pos2”.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 - Samples collect from the subject 519 at different time points – exacerbation 
(Exacerbation), 2 weeks after exacerbation (Pos2), and 6 weeks post exacerbation at clinical 
recover (Recovery) - taxonomic composition is shown at the genera level. Plot showing the 
relative abundances, each column in the plot represents a time of sample collection, and each 
color in the column represents the relative abundance of each taxon at genera level.  
Streptococcus, Rothia and Veillonella were the most prominent genera across the three 
sampling times. 
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3.5.2. Subject 587 
Subject 587 was a 77 years old man, at GOLD 1 of the disease that is 
considered a very mild stage of COPD. This individual was a former smoker, even 
though he just smoked for one year. At AECOPD, he did not receive any treatment 
with antibiotic nor corticosteroid. Besides the exacerbation sample (“Exacerbation”), 
it was also collected a sample after two weeks of exacerbation (“Pos2”) and after 6 
weeks (“Recovery”). 
 Firmicutes, Fusobacteria, and Proteobacteria were the phyla found at higher 
abundances (Appendix 6), while Streptococcus, Veillonella, Neisseria, and Rothia 
were the most common genera across all samples collected from this subject 
(Figure 16).  
With regard to alpha-diversity over time, the saliva microbiome 2 weeks after 
the exacerbation was more diverse than at exacerbation although less diverse than 
at recovery (Table 6). 
 
Table 6 - Bacterial richness (number of OTU’s observed and Chao1 estimator) and diversity 
(Shannon and Simpson indexes) of the samples collected from patient 587. “Exacerbation” – at 
exacerbation, “Pos2” – 2 weeks after exacerbation, “Recovery” – 6 weeks after exacerbation. 
 Richness Diversity 
 Observed Chao1 Shannon Simpson 
587 – Exacerbation 1122 1983.37 3.92 0.93 
587 – Pos2 1091 1991.57 3.99 0.94 
587 - Recovery 1323 2075.90 4.06 0.94 
 
Over the time, there was an increase in the relative abundance of Leptotrichia 
and Prevotella, a pattern was also found in patient 519. Neisseria was present with 
a really small relative abundance (0,3%) in “Pos2” phase, which also showed a 
decrease in Streptococcus, while Rothia, Veillonella, and Haemophilus increased 
when compared with “exacerbation” and “Recovery”. When comparing “Pos2” with 
“Recovery”, Veillonella, Rothia, and Haemophilus decreased in relative abundance, 
while Leptotrichia increased. On the other hand, Haemophilus and Neisseria 
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decreased in relative abundance in “Recovery”, when comparing with 
“Exacerbation”, as shown in figure 16. 
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Figure 16 - Samples collected from subject 587 at different time points – exacerbation 
(Exacerbation), 2 weeks after exacerbation (Pos2), and 6 weeks post exacerbation, after clinical 
recovery (Recovery) - taxonomic composition is shown at the genera level. Plot showing the 
relative abundances, each column in the plot represents a time point of sample collection, and 
each color in the columns represents the relative abundance of each taxon at the genera level. 
At pos2, there was a decrease in the relative abundance of Streptococcus and Neisseria, and 
an increase in Veillonella, Rothia and Haemophilus, when comparing with the other two 
sampling moments. 
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3.5.3 Subject 526 
Subject 526 was a 78 years old individual, who had severe COPD - stage 3, 
according to GOLD COPD stages. He was also the heavier smoker individual of the 
group, who used to smoke 60 cigarettes per day during 36 years. At AECOPD, this 
subject was treated with Methylprednisolone, a corticosteroid frequently used in 
patients with COPD (Hunter & King 2001), that  is used to suppress the immune 
system and decrease inflammation (Umberto Meduri et al. 2002). This was the only 
subject where a sample was collected at recovery, and post recovery, i.e. 8 months 
after exacerbation (“Recovery_B”). With this time point we aimed to compare the 
differences between two time points, of the same subject, that are clinically 
considered as being the same, since after 6 weeks of exacerbation a COPD patient 
is considered to be completely recovered (Seemungal et al. 2000). 
 Proteobacteria and Firmicutes were the most prominent phyla (Appendix 6) 
among all samples of this patient, whereas Neisseria and Haemophilus were the 
most abundant genera (Figure 17). With regard to the microbiome dynamics, the 
sample collected at “exacerbation” had higher diversity than at “recovery” (Table 7), 
that it was accompanied by an increase in Firmicutes and Proteobacteria over time 
(Appendix 6).  
 
Table 7 - Bacterial richness (number of OTU’s observed and Chao1 estimator) and diversity 
(Shannon and Simpson indexes) of the samples collected from patient 526. “Exacerbation” – at 
exacerbation, “Recovery” – 6 weeks, and “Recovery_B” – 8 months after exacerbation. 
 Richness Diversity 
 Observed Chao1 Shannon Simpson 
526 – Exacerbation 652 1076.86 3.29 0.87 
526 – Recovery 650 1107.88 3.06 0.86 
526 – Recovery_B 448 833.23 2.61 0.77 
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Furthermore, when comparing the two samples collected at recovery, 
diversity decreases at “Recovery_B” (Table 7). Additionally, in terms of phylogenetic 
composition, the sample collected 8 months after exacerbation, appears to be more 
different from the other samples collected, as it can be seen by the PCoA that was 
done with the unweighted UniFrac metric (Figure 11). As it can be seen by figure 
17, Haemophilus, Neisseria, and Rothia had extremely differences in relative 
abundances, comparing the two recovery times of collection. However, the relative 
abundance of Streptococcus was identical at “Recovery” (10%) and “Recovery_B” 
(9,4%), being the only genus that presented identical relative abundances at 
recovery, i.e. after 6 weeks and after 8 months of exacerbation (Figure 17).  
Interestingly the relative abundances of Neisseria were exactly the same at 
the samples collected at exacerbation and 6 weeks after (38%), while it increased 
at 8 months after exacerbation (52,8%) (Figure 17). 
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Figure 17 - Samples collected from the subject 526 at different time points – exacerbation 
(Exacerbation), 6 weeks post exacerbation (Recovery) and 8 months after exacerbation 
(Recovery_B). Taxonomic composition is shown at the genera level. Plot with the relative 
abundances, each column of the plot represents a time point of sample collection, and each 
color in the columns represents the relative abundance of each taxon at the genera level. The 
microbial composition of the two recovery sampling times was remarkably different with 
exception for the relative abundance of Streptococcus.   
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3.5.4 Subject 555 
Subject 555, a 76 years old man, had moderate COPD (GOLD 2) and, at 
exacerbation, was treated with Levofloxacin, a broad-spectrum antibiotic that is 
frequently used in patients with COPD (Miravitlles & Torres 2004). This subject was 
the only one from which a sample at “Recovery” was not collected.  
Overall, the two samples collected showed a different diversity, being the 
“Pos2” sample more diverse than the sample collected at “Exacerbation” (Table 8).  
 
Table 8 - Bacterial richness (number of OTU’s observed and Chao1 estimator) and diversity 
(Shannon and Simpson indexes) of the samples collected from patient 555. “Exacerbation” – at 
exacerbation, “Pos2” – two weeks after exacerbation. 
 Richness Diversity 
 Observed Chao1 Shannon Simpson 
555 – Exacerbation 874 1435.70 4.02 0.92 
555 – Pos2 1121 1635.04 4.13 0.94 
 
Actinobacteria and Firmicutes were the predominant phyla (figure 5 and 
Appendix 6), whereas, Rothia, Streptococcus, and Veillonella were the genera with 
the highest relative abundance (Figure 18) 
The relative abundances of Rothia, Neisseria, and Haemophilus were higher 
at the “exacerbation” sample than in the sample collected after 2 weeks, while the 
opposite trend was observed with Veillonella, Prevotella, and Leptotrichia. The 
relative abundance of Streptococcus did not suffer major changes (16,3% at 
“Exacerbation”, and 17,5% at “Pos2”) (Figure 18).  
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Figure 18 - Samples collected from subject 555 at two different time points – exacerbation 
(Exac) and 2 weeks after exacerbation (Pos2). Taxonomic composition is shown at the genera 
level. a. Plot showing the relative abundances, each column in the plot represents a time point 
of sample collection, and each color in the columns represents the relative abundance of each 
taxon at the genera level. The relative abundances of Rothia, Neisseria, and Haemophilus were 
higher at the “Exacerbation” sample than in the “Pos2” sample, while the opposite trend was 
observed with Veillonella, Prevotella, and Leptotrichia. 
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3.5.5 Subject E44 
Subject E44, a 73 years old man, suffered from moderate COPD (GOLD 2) 
and was the only individual, at this study, that never smoke, nor did receive any 
treatment with antibiotics or corticosteroids, at AECOPD. Only samples at 
exacerbation and 6 weeks after exacerbation (“Recovery”) were collected. 
The sample collected at exacerbation was more diverse than the sample 
collected at recovery, table 9.  
 
Table 9 - Bacterial richness (number of OTU’s observed and Chao1 estimator) and diversity 
(Shannon and Simpson indexes) of the samples collected from patient E44. “Exacerbation” – 
exacerbation and “Recovery” – 6 weeks after exacerbation. 
 Observed Chao1 Shannon Simpson 
E44 – Exacerbation 688 1309.28 4.08 0.95 
E44 – Recovery 955 1584.24 3.94 0.94 
 
 
Firmicutes, Proteobacteria, and Actinobacteria were the most common phyla 
(Appendix 6). Streptococcus, Neisseria, Veillonella, and Haemophilus were the 
predominant genera, in the overall composition of the two samples, as shown in 
figure 19. 
No major differences were found between the two moments of sample 
collection. Nevertheless, small differences could be found, such as the relative 
abundance of Streptococcus, Neisseria, and Rothia that decreased at “Recovery”, 
while there was an increase in the proportion of Neisseria and Haemophilus, at the 
second time of collection (Figure 19).   
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Figure 19 - Samples collected from subject E44 at two different time points – exacerbation 
(Exac) and 6 weeks post exacerbation at clinical recovery (Recovery). Taxonomic composition 
is shown at the genera level. a. Plot showing the relative abundances, each column in the plot 
represents a time point of sample collection, and each color in the columns represents the 
relative abundance of each taxon at genera level. The relative abundance of Streptococcus, 
Neisseria, and Rothia that decreased at “Recovery”, while there was an increase in the 
proportion of Neisseria and Haemophilus. 
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3.5.6 Subject 616 
Subject 616 was the youngest individual of the group, 54 years old. As with 
most of the subjects, 616 suffered severe COPD (GOLD 3) and was a former 
smoker. At exacerbation, he was treated with Azithromycin. Besides the sample 
collected at exacerbation, a sample at recovery (“Recovery”) was also collected. 
The sample collected at AECOPD from this patient was the least diverse 
sample of all, and likewise it was also less diverse than the sample collected at 
recovery, as it can be seen in table 10.  
 
Table 10 - Bacterial richness (number of OTU’s observed and Chao1 estimator) and diversity 
(Shannon and Simpson indexes) of the samples collected from patient 616. “Exacerbation” – at 
exacerbation and “Recovery” – 6 weeks after exacerbation. 
 Richness Diversity 
 Observed Chao1 Shannon Simpson 
616 – Exacerbation 279 512.68 2.26 0.74 
616 – Recovery 802 1275.69 3.69 0.92 
 
 
Firmicutes and Actinobacteria were the most common phyla (Appendix 6), 
and Veillonella, Streptococcus, Leptotrichia and Rothia were the most abundant 
genera, among the two times of sample collection.  
During exacerbation, two Firmicutes genera – Veillonella and Streptococcus 
accounted for around 90% of the total relative abundance. This proportion 
decreased dramatically during recovery were these two genera represented around 
22% of all genera (Figure 20).  
During recovery there was an increase in Rothia compared to exacerbation. 
Actinomyces, Atopobium, Oribacterium, Leptotrichia, Neisseria, and Haemophilus 
were absent during exacerbation, while at recovery they accounted for over 55% of 
all genera present in the sample (figure 20). 
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Figure 20 - Samples collected from subject 616 at two different time points – exacerbation 
(“Exac”) and 6 weeks post exacerbation, after clinical recovery (“Recovery”). Taxonomic 
composition is shown at the genera level. a. Plot showing the relative abundances, each 
column in the plot represents a time point of sample collection, and each color in the columns 
represents the relative abundance of each taxon group at the genera level. Veillonella and 
Streptococcus accounted for around 90% of the total relative abundance at “Exacerbation”, 
while at “Recovery” this proportion decreased for around 22% of all genera. 
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3.5.7 Subject S29 
Subject S29, a 58 years old man, was the only subject of the group to be in 
the most severe stage of the disease (GOLD 4). At exacerbation, he was treated 
with azithromycin. A sample at exacerbation (“Exacerbation”) and 6 weeks after 
exacerbation (“Recovery”) was collected.  
Proteobacteria and Firmicutes were the most abundant phyla, with an 
increase in the relative abundance of Proteobacteria and a decrease in Firmicutes, 
over time (Appendix 6). On the other hand, Streptococcus, Neisseria, and 
Haemophilus were the most common genera, in both samples collected (Figure 21).  
Contrary to what was observed in the other individuals, the sample collected 
from S29 at exacerbation had higher richness and diversity than the one collected 
at recovery (Table 11).  
 
Table 11 - Bacterial richness (number of OTU’s observed and Chao1 estimator) and diversity 
(Shannon and Simpson indexes) of the samples collected from patient S29. “Exacerbation” – 
exacerbation and “Recovery” – 6 weeks after exacerbation. 
 Observed Chao1 Shannon Simpson 
S29 – Exacerbation 899 1636.23 3.93 0.95 
S29 – Recovery 798 1338.08 3.45 0.89 
 
 
In terms of community dynamics, the relative abundances of Streptococcus, 
and Rothia decreased in recovery, whereas the relative abundance of Neisseria and 
Haemophilus increased (Figure 21). 
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Figure 21 - Samples collect from the subject S29 at two different time points – exacerbation 
(“Exac”) and 6 weeks post exacerbation at clinically recover (“Recovery”) - taxonomic 
composition is shown at the genera level. a. Plot showing the relative abundances, each 
column in the plot represents a time of sample collection, and each color in the column 
represents the relative abundance of each taxon group at genera level. The relative 
abundances of Streptococcus, and Rothia decreased at “Recovery”, while the relative 
abundances of Neisseria and Haemophilus increased. 
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Chapter IV – Discussion 
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4.1. Methodology 
  
One of the aims of this study was to establish protocols for the saliva 
collection, conservation, transport and laboratorial treatment to reach good overall 
sample quality. Even though, a recent study from Lim et al. (2017), suggested that 
the collection method and DNA extraction methods, do not affect the saliva 
microbiome profiles obtained (Lim et al. 2017), it was pivotal to access the factors 
of variability that were introduced in the elapse of this study, and determine if and 
how they influenced our results. 
The procedure was all the same for all samples collected, with exception for 
the volume of saliva collected, 4 out of the 17 samples had 500 μL of saliva, instead 
of 1 mL. Even though the protocol has been adjusted to correct for this fact, it could 
have introduced some variability on our results. Based on the results from the 
PERMANOVA analysis of the Bray-Curtis variances, one cannot say that this was a 
relevant variation, since no statistically differences were found between the two 
volumes of sample collected. Even though, no statistically differences were found, 
we would suggest that in a subsequent study the volume of saliva collected be taken 
into consideration, since this can be a factor of variability and lead to differences in 
the obtained results.   
 Considering the time constrains, it was not possible to relate all the clinical 
characteristics of the patients (Appendix 4) with the metagenomic data. Thereby, in 
a future study this characterization should be taken into account in order to do a 
more detailed study.     
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4.2. A “core” microbiome in saliva samples from patients with 
COPD 
  
In this study, the predominant phyla found in all saliva samples were 
Firmicutes, Proteobacteria, Actinobacteria, Fusobacteria, and Bacteroidetes. This is 
consistent with the results from sputum (Wang et al. 2016; Su et al. 2015), BAL (Erb-
Downward et al. 2011), and oropharynx samples (Park et al. 2014), collected from 
patients with COPD, although BAL samples seem slightly richer in Fusobacteria.  
At genera level, Streptococcus, Neisseria, Rothia, Veillonella, Haemophilus, 
and Leptotrichia were the most abundant. Even though most of the genera detected 
are in accordance with Wang et al. (2016),  Erb-Downward et al. (2011), and Su and 
colleagues (2015), in samples collected from patients with COPD, in our samples 
we did not find Pseudomonas or Moraxella, two genera belonging to the lung 
microbiome, as identified both by culture dependent (Sethi et al. 2002), and 
independent methods (Wang et al. 2016; Erb-Downward et al. 2011). However, Su 
et. al (2015) did not find an increased presence of this genera either, based on a 
culture independent method, which suggests that there is high variability in genera 
associated with the COPD microbiome. Therefore other studies are needed to reach 
a better characterization of this microbiome.  
Interestingly, Porphyromonas, a genus frequently found in the healthy human 
oral microbiome at higher relative abundances (Zaura et al. 2009), was found by us 
as representing only a small percentage of the overall microbiome composition, 
although being present in 16 out of the 17 samples that were studied.       
The “core microbiome” of the lower airway has been described as remarkably 
similar to the saliva microbiome. This supports the theory of Charlson et al., 2011, 
later demonstrated by Bassis et al. (2015) and Dickson and colleagues (2015), that 
defends that the upper airway, especially the oral cavity microbiome, shapes the 
lower airway, through microaspiration. Therefore, and based on the results from this 
study, we assume that saliva is a representative sample for the study of the lung 
microbiome in patients suffering with COPD. 
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4.3. Microbiome shifts after AECOPD treatment 
 
The most notably overall changes in community composition over time were 
found in the first samples taken after treatment for exacerbation (pos2). This was 
also shown in the studies from Huang et al. (2014) and Wang et al. (2016), with an 
increase in alpha-diversity, using both richness and diversity in samples collected 
two weeks after exacerbation. Additionally, at our results, it was found a microbial 
compositional shift towards an increase in the relative abundance of Veillonella, 
Rothia, Oribacterium and Leptotrichia at this collection time. These results are not 
in agreement with the study from Huang and colleagues, that also suggested that 
there were higher differences at the first collection time after treatment, although 
these differences reflect alterations in the relative abundances of genera belonging 
to the Proteobacteria phyla (Huang et al. 2014).   
Likewise large differences were found between the samples collected at 
“pos2” and at recovery, where there was a significant decrease in the relative 
abundance of Rothia, Oribacterium, and Veillonella, in contrast with an increase in 
Neisseria.  
 At recovery, the diversity of the microbial community decreased, becoming 
more similar to the diversity level at exacerbation. No differences were found at 
phyla level when comparing the relative abundances from this two collection time 
points. However, there was a decrease in the relative abundance of the genus 
Streptococcus, which is in accordance with the results from Liu et al. (2017), for 
sputum and oropharyngeal samples.  
Streptococcus is one of the genera frequently found at higher abundances in 
sputum samples collected during AECOPD, through culture dependent 
(Hirschmann 2000) and independent methods (Millares et al. 2014).  Since there 
was an overall reduction in the relative abundance of this genera over time perhaps 
this genus could be used to evaluate if the individual has already recovered from 
the exacerbation or not. Although, further studies should be done to confirm if this 
trend is observed in a larger cohort, as well as if there is an overall increase of 
Streptococcus before exacerbation until the onset of this acute event, where this 
genus would have, supposedly, its higher abundance. 
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  In regard to the two samples from the same subject, patient 526, that were 
collected at recovery i.e. 6 weeks after exacerbation (Recovery), and 8 months after 
(Recovery_B), and since these two samples were collected at the same stadium of 
the disease, one would expect that these would be more similar. However, the 
sample collected at 8 months after exacerbation had less richness and diversity that 
the one collected 6 weeks after exacerbation. Likewise, the microbial composition 
of the two samples are notably different (see Figure 11 and 17), with exception for 
the relative abundance of the genus Streptococcus, that had a similar relative 
abundance in the two collection time points. 
These results suggest that perhaps there are other factors, non-related with 
the disease that may induce differences in the microbial composition. However, the 
fact that the Streptococcus genus was found at similar relative abundances at the 
two collection points, reinforces the idea that Streptococcus could be used for 
motorizing the progression of the disease.  
 From our results, we cannot conclude when the microbiome is considered to 
be stable, and since our sampling time began at exacerbation, one still needs to 
collect samples from the whole cycle of the disease, i.e. to start the collection of 
samples before exacerbation. For that a larger longitudinal study should be done, 
with a larger cohort and with more sampling time points i.e. once a month until 
exacerbation, during the acute event, two weeks after exacerbation, 6 weeks after 
exacerbation and then returning to monthly sampling collections. Studies 
comprehending pre-exacerbation and post-exacerbation collection time points were 
already done to study COPD, but using sputum samples ( Wang et al. 2016; Huang 
et al. 2014). 
  However, from our knowledge, there are no studies like this using saliva, 
which would allow us to further comprehend the saliva microbiome dynamics at 
stability (before exacerbation) and which changes occur just before the onset of an 
exacerbation. Gaining this knowledge would be important to validate saliva 
microbiome as a potential biomarker for predicting exacerbations in patients with 
COPD. Furthermore, questions such as how the microbiome evolves after an 
exacerbation, how it is affected by the prescribed treatment, when does it become 
similar to the microbiome at stability, or does it never return to the same point. 
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Nevertheless, we suggest to focus further studies on the dynamics of the 
Streptococcus genus, which from our results seems to be the genus that should be 
more deeply monitored, in patients suffering from COPD.  
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4.4. Inter-subject variation 
  
From our results it was evident that, even though there are some statistically 
significant differences over time, the strongest evidence was that there was an 
enormous heterogeneity among patients with COPD. These results are in 
accordance with Su et al. (2015) that showed that even though there are some 
patterns across patients, the microbiome dynamics were almost personalized to 
each patient. So it will be important to focus on the microbiome variation in smaller 
groups of subjects, stratified according to their GOLD grade of disease and other 
clinical information, to be able to determine how the microbiome truly varies after an 
acute event of COPD.  
In accordance with the overall observation, also the samples collected from 
patients 519, 587, and 555 had higher diversity and richness at 2 weeks post 
exacerbation. However, the three patients received different treatments, while 519 
and 555 were treated with an antibiotic, patient 587 did not receive any treatment, 
which may suggest that these differences are not dependent of the treatment 
administrated.  
Additionally, when comparing the samples collected at exacerbation and after 
6 weeks, from patients treated with antibiotics – patient 616 and S29 -, on patient 
616, it was found an increment in richness and diversity, while on patient S29 the 
opposite trend was found. Patient 526 was the only individual of the cohort that was 
treated with a corticosteroid at exacerbation, when comparing the samples collected 
at exacerbation and the two collected at recovery, it was evident that there was a 
decrease of diversity over time, while there was an increase in Proteobacteria and 
Firmicutes. These results are in accordance with what Wang et al. (2016) and 
Huang et al. (2014) observed in individuals treated only with corticosteroids. 
Given our data, one can speculate that treatment for AECOPD overtime, can 
modify the microbiome community composition of the patients, and therefore 
contribute to the increase of disease severity and further enhancement of the risk 
for new exacerbations, as suggested by Huang et al. 2017. To confirm that, 
however, our approach must be strengthen with more longitudinal studies with 
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patients receiving different treatments and being followed over longer periods of 
time. 
When grouping the patients by the severity of disease from mild to moderate 
(GOLD 1 and 2) and severe to very severe (GOLD 3 and 4), one can see that in our 
cohort, the samples collected from patients in the lower stages of the disease 
present an overall higher richness and diversity. With exception for patient S29, that 
was in the very severe stage of the disease and presents also high diversity in his 
samples. On the other hand, samples collected from patients in the severe stage of 
the disease – patient 616 and 526 -, had lower diversity and richness. This results 
disagree with the Pragman et al. (2012), and Garcia-Nuñez and colleagues (2014), 
which shown that patients in the later stages of the disease has a higher diversity 
than the ones at the less severe stages. However, our results are in accordance 
with Erb-Downward et al. (2011). Given the heterogeneity of the results, presented 
by us and by other authors, more studies comprehending larger cohorts with 
subjects in different stages of COPD should be performed.  
 Our results support the idea that despite the fact that there was a core 
microbiome in the saliva of all patients with COPD, there were also strong inter-
individual variations, suggesting that every subject has a unique microbiome that 
may play a role in the etiology of the disease, leading to different manifestation and 
progression of the disease among different subjects (Zarco et al. 2012). Therefore, 
the study of the individual human microbiome may be used to assess the 
progression of the disease, to evaluate if a certain treatment is working, or not, and 
how this treatment may compromise the microbiome and consequently the disease 
progression in a long term. These evidences may suggest that the study of the 
microbiome should indeed be incorporated into the emergent field of personalized 
medicine (Sonnenburg & Fischbach 2011).  
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4.5 Saliva as a potential target for COPD biomarkers 
 
As shown by our results and other studies, COPD is a heterogeneous and 
complex lung disease. So, the identification of clinical biomarkers would help to 
diagnose the disease, monitor its progression, evaluate the response to therapy 
(Shaw et al. 2014) decide the best treatment to apply or even to predict the onset of 
exacerbation.  
Since collecting saliva is a non-invasive and easy process, and, as shown 
above, it is possible to detect the “core microbiome” in these samples, this 
methodology becomes highly interesting under this scope. Furthermore, as 
suggested by Pragman et al. (2012), the study of the oral microbiome may be 
important to understand the disease progression and exacerbations. This work was 
then the first step to advance our understanding about the role of saliva microbiome 
in COPD and to highlight a new potential source of biomarkers for this disease. 
Nevertheless, much more studies must be done to support this claim, because 
strong statistical evidence is needed to establish a clinical biomarker based on the 
saliva microbiome. 
 However, considering the fact that it was observed an overall decrease in the 
relative abundance of Streptococcus over time, this could become a good biomarker 
to evaluate the disease progression after an exacerbation. Also Cameron et al. 
(2016), with sputum samples, and Diao et al. (2017) with oropharyngeal and sputum 
samples, suggested that changes in  the abundance of Streptococcus may allow to 
differentiate between healthy and COPD subjects, as well as to use it as a predictor 
of COPD progression. Again, further studies with larger cohorts should be done to 
confirm it.  
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4.6. Limitations and further perspectives 
 
An important limitation of this study was that the microbiome analyses were 
carried out on only 17 saliva samples from 7 different patients with COPD, which 
limits the ability to conduct rigorous statistical analysis. For a longitudinal study, this 
was an extremely small sample size, therefore extrapolating this results to a broader 
group of patients should be cautiously done. Also the fact that only samples at 
exacerbation and post-exacerbation were analyzed, and the heterogeneity of 
subjects and time points of sample collection per subject, make very difficult to 
validate the results. Indeed, this study must only be considered a pilot project that 
managed to implement the methodology so that a valid population study can be 
conducted, involving a larger number of patients and pre-exacerbation (stable state) 
samples as well. 
 An additional limitation of this study, was that only patients suffering with 
COPD were analyzed, with no healthy or control subjects (subjects that were not at 
exacerbation). Data from these populations would be pivotal to define the normal 
saliva microbiota and what is altered in COPD, as well as the changes in microbial 
composition at different disease phenotypes.     
For a future study, it would be interesting to do a deeper analyzes of the saliva 
samples collected, such as a standard culture, to access the bacterial load in the 
sample, as well as the presence of typical COPD pathogens (e.g. Moraxella 
catarrhalis, Staphylococcus aureus) that are found in other types of samples, e.g. in 
sputum. This would be interesting to validate the saliva sample as a good sample 
to study the microbiome in patients with COPD, as well as to differentiate between 
bacterial and eosinophilic exacerbations. A study like this would allow us to study 
the microbial differences in the two types of these acute events, and could be 
interesting for clinical purposes. Since, antibiotics are often prescribed for the 
treatment of exacerbations, and since there are some non-bacterial exacerbations, 
if we could distinguish the type of exacerbation based on the microbial composition, 
a more adjusted and effective treatment could be prescribed.     
Another drawback was the fact that this was a metagenomic study based on 
the 16S rRNA gene amplification alone. A shotgun metagenomics approach would 
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give much more information, not only about the bacterial composition of the 
samples, but also about their biological functions, as encoded in the genomes 
(Sharpton 2014). Ideally, in order to achieve the most complete functional 
characterization of the microbiome, a combination of shotgun genome sequencing, 
metatranscriptomics, metabolomics, metaproteomics, and viromics would be 
necessary (Bikel et al. 2015). A study comprehending all these approaches, 
although extremely ambitious and costly, would be highly informative about the 
interplay between saliva microbiome and COPD. 
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Chapter V – Conclusions 
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 Given the nature of this study, a lot of questions arose from it which should 
be answered in further studies, as well as some suggestions that may allow us to 
extend our knowledge in this emerging field. The major limitation of this study was 
the small number of samples that were analyzed, which limited the ability to conduct 
rigorous statistical analysis. In further studies, the sample size should take into 
consideration, as well as the selection of sampling times, patients’ characteristics, 
and the usage of different treatments for exacerbation. In order to do a better 
characterization of the saliva microbiome and its dynamics in patients suffering with 
COPD. 
Even considering all the mentioned limitations of this study, we could also 
extract from it some conclusions. The main objective of this study was to check if 
the saliva microbiome could be used to evaluate some of the clinical outcomes of 
respiratory diseases, such as COPD. In doing so, we proposed to study the 
dynamics of the saliva microbiome at exacerbation and how the microbial 
community evolved after that acute event. Even though this study comprehends a 
very small group of patients with COPD, the results of this study indicated that saliva 
microbiome should be taken into consideration to improve our understanding of the 
pathology itself as well as of the exacerbation event. We also proposed that 
Streptococcus should be considered as a potential biomarker for disease 
progression. Additionally, we envisage that the study of the saliva microbiome in 
patients with COPD may be important in the scope of personalized medicine. 
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1. Table that summarizes published studies that used 16S rRNA gene sequencing to describe the airway 
microbiome. 
Type of sample Authors Year Type and number of 
patients 
Significant findings 
Nasopharyngeal and 
oropharyngeal 
Charlson et 
al. 
2010 62 healthy subjects – 29 
smokers and 33 
nonsmokers 
Community composition exhibited minimal body site variation.  
BAL samples Erb-
Downward 
2011 7 healthy smokers, 3 
never smokers and 4 
patients with COPD 
There is a core pulmonary microbiome that includes: Pseudomonas, 
Streptococcus, Prevotella, Fusobacterium, Haemophilus, 
Veillonella, and Porphyromonas.   
Patients with moderate and severe COPD have lower community 
diversity. 
Upper tract: oral and 
oro-/nasopharyngeal swabs. 
Lower tract: glottis,  BAL, 
and lower airway protected brush 
Charlson et 
al. 
2011 6 healthy subjects The community composition is indistinguishable in upper and lower 
tract, although bacteria are present in the lungs of healthy subjects 
at lower levels compared to the upper respiratory tract. 
Sputum, bronchial aspirate, 
Bronchiolar Alveolar Lavage 
(BAL) and bronchial mucosal 
Cabrera-
Rubio et al. 
2012 6 patients with COPD Sputum samples showed significant lower diversity than the other 
three. 
BAL and bronchial mucosal samples showed similar compositions 
in contrast with the other two samples. 
Oral and Alveolar Morris et al. 2013 64 healthy subjects, being 
45 nonsmokers and 19 
smokers 
Most bacteria identified in alveolar lavages were also in the oral 
microbiome.  
Although specific bacteria (Enterobacteriaceae, Haemophilus, and 
Methylobacterium) appear in significant higher abundance in the 
lungs. 
Oral, BAL, nasal Bassis et al. 2015 28 healthy subjects The bacterial communities of the lungs were significantly different 
from those of the nose and mouth. However, the bacterial 
communities of healthy lungs shared significant membership with 
the mouth but not with nose.  
 
Oropharyngeal and sputum 
Liu et al. 2017 114 samples from 4 
patients with COPD, 
suffering from severe 
AECOD 
Sputum microbiome is similar to the oropharyngeal microbiome. 
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2. Table that summarizes published studies that analysed the microbiome dynamics in AECOPD. 
 
Authors Year Sampling Significant findings 
Huang et 
al. 
2010 Endotracheal samples from 8 different 
patients at exacerbation 
 Patients exhibiting communities with significantly fewer taxa, tended to have more 
members of Pseudomonadaceae. Patients with richer communities tend to have 
more members of Clostridiaceae, Lachnospiraceae, Bacillacee, and 
Peptostreptotaceae. 
 A core microbiome of 75 taxa, belonging to 27 families, was detected in all patients, 
including members of the Enterobacteriacee, Campylobacteraceae, and 
Helicobacteraceae family, as well as potential pathogens such as A. cryaerophilus, 
B. diminuta, L. integrans, and P. aeruginosa. 
Huang et 
al. 
2014 Sputum samples from 12 different 
patients were collected before, at onset 
of, and after exacerbation (2 weeks and 6 
weeks after) 
 At exacerbation, predominantly, members of Proteobacteria were enriched, 
compared with the samples collected at pre-exacerbation. 
 The major difference in the community composition was found at post treatment, 
when compared, with pre and at exacerbation. At this time point, the majority of 
taxa decreased in abundance, especially members of Proteobacteria. 
 Patients treated with antibiotics showed a reduced abundance of Proteobacteria. 
Patients treated with steroids and antibiotics showed and increase in 
Proteobacteria. Treatment with only steroids lead to an enrichment in 
Proteobacteria and members of Bacteriodetes and Firmicutes. 
Millares 
et al. 
2014 Sputum samples from 16 patients with 
COPD were collected before and at 
exacerbation 
 Increase in abundance of taxa typically associated with COPD, at AECOPD, such 
as Streptococcus, Pseudomonas, Moraxella, Haemophilus, Neisseria, 
Archromobacter and Corynebacterium, compared with samples collected before. 
Millares 
et al. 
2015 Sputum samples from 8 severe patients 
with COPD collected before and at 
exacerbation 
 No significant differences were found in the community composition among the two 
collection times. 
Su et al. 2015 Sputum samples from 6 severe patients 
with COPD collected at exacerbation, and 
7 to 16 days after exacerbation 
 Bacterial community typically found in the patients with COPD: Acinetobacter, 
Prevotella, Neisseria, Rothia, Lactobacillus, Leptotrichia, Streptococcus, 
Veillonella, Pasteurella, Klebsiella and Actinomyces. 
 Microbial communities showed significant variation among patients, contributing to 
patterns almost always personalized to each patient. 
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Wang et 
al. 
2016 Sputum samples from 8 different patients 
were collected before, at exacerbation, 2 
weeks post and 6 weeks post-
exacerbation 
 At exacerbation, it was found an overall reduced alpha-diversity, with a non-
significant increase abundance of Proteobacteria, and decrease in Firmicutes, 
compared with stable states. 
 It was found also differences in microbial composition, in eosinophilic and bacterial 
exacerbations. While bacterial exacerbations showed an overall reduced alpha-
diversity and Firmicutes, and an increase of Proteobacteria. While a decreased 
Proteobacteria: Firmicutes ratio was found in the eosinophilic exacerbations.  
 Differences were also found when different treatments were applied. When just 
corticosteroids were use, it was found a decrease microbial alfa- diversity with 
increase in Proteobacteria and Firmicutes. The opposite trend was found in 
individuals treated with only antibiotics. 
Liu et al. 2017 Oropharyngeal and sputum samples were 
collected from 4 different patients, at 
exacerbation and the following days of 
hospitalization (14-17 days) 
 During AECOPD Psychrobacter, Lactobacillus, Rothia, Prevotella, Neisseria, 
Streptococcus, Haemophilus, Actinomyces, Leptotrichia, and Aspargillus, showed 
high relative abundance. 
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3. Informed Consent  
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4. List of all tests collected to clinically characterize the patients 
 
Characteristics  
 Age (years) 
 Gender 
 GOLD classification 
 Smoking Status 
 Other comorbidities 
 
Lung Function Tests 
 Predicted FEV1 
 FVC 
 FEV1 
 FVC 
 FEV1/FVC 
 
Muscular and Functional Tests 
 Maximum Inspiratory Pressure 
 Maximum Expiratory Pressure 
 Quadriceps muscle strength 
 Handgrip 
 5 repetition sit-to-stand 
 1 minute sit-to-stand 
 
Patient Reported Outcomes 
 Frequency of exacerbations 
 Dyspnea 
o Modified British Medical Research Council questionnaire 
o Borg Scale 
 Fatigue 
 Anxiety Score 
o Hospital Anxiety and Depression Scale M   
 Depression Score 
o COPD Assessment Test M, (IQR) 
o St. George Respiratory Questionnaire 
 Symptoms score 
 Activity score 
 Impact score 
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5. Volume of saliva and DNA concentration per sample  
Table 3. Volume of saliva and DNA concentration, given by Qubit, per sample. 
 
Patient 
 
 
 
Stable (pre exacerbation) Exacerbation 
Recovery 
Post 2 weeks Post 6 weeks Post 8 months 
519 
 Volume of Saliva: 1 ml 
DNA concentration: 19,36 
ng/µL 
Volume of Saliva: 1 ml 
DNA concentration: 31,8 
ng/µL 
Volume of Saliva: 1 ml 
DNA concentration: 94,8 
ng/µL 
 
526 
 Volume of Saliva: 1 ml 
DNA concentration: 42,8 ng/µL 
Volume of Saliva: 1 ml 
Qubit: 81,0 ng/µL 
 Volume of Saliva: 1 ml 
DNA concentration: 22,6 
ng/µL 
555 
 Volume of Saliva: 500 μL 
DNA concentration: 63,8 ng/µL 
 
Volume of Saliva: 1 ml 
DNA concentration: 78,6 
ng/µL 
 
 
 
 
S29 
 Volume of Saliva: 500 μL 
DNA concentration: 11,4 ng/µL 
 
 
Volume of Saliva: 1 ml 
DNA concentration: 27,2 
ng/µL 
 
 
E44 
 Volume of Saliva: 500 μL 
DNA concentration: 12 ng/µL 
 Volume of Saliva: 1 ml 
DNA concentration: 37,6 
ng/µL 
 
587 
 Volume of Saliva: 500 μL 
DNA concentration: 12,2 ng/µL 
Volume of Saliva: 1 ml 
DNA concentration: 24,8 
ng/µL 
Volume of Saliva: 1 ml 
DNA concentration: 60,6 
ng/µL 
 
616 
Volume of Saliva: 1 ml 
DNA concentration: 2,06 
ng/µL 
Volume of Saliva: 1 ml 
DNA concentration: 30,6 ng/µL 
 
 Volume of Saliva: 1 ml  
DNA concentration: 30,2 
ng/µL 
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6. Taxa plots at phyla level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. - Samples have been grouped and averaged by time of collection – exacerbation 
(Exac), 2 weeks after exacerbation (Pos2), and 6 weeks (Recovery) and 8 months ) post 
exacerbation (Recovery_B). Taxonomic composition was shown at phyla level. Each column 
in the plot represents a time of sample collection, and each color in the columns represents 
the relative abundance of the total sample divided by different phyla. Across the four 
sampling times, the most abundant phyla are Firmicutes, Proteobacteria, and 
Actinobacteria.   
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Figure 2. - Samples collect from the subject 519 at different time points – exacerbation (Exac), 2 
weeks after exacerbation (Pos2), and 6 weeks post exacerbation after clinical recovery (Recovery). 
Taxonomic composition is shown at the phyla level. Each column in the plot represents a time point of 
sample collection, and each color in the columns represents the relative abundance of each taxon 
group at phyla level. Across the three samples, the most abundant phyla were Firmicutes, 
Actinobacteria and Fusobacteria. The relative abundance of Firmicutes decreases after “Exac”, and 
remains constant in “Pos2” and “Recovery”. 
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Figure 3. - Samples collect from the subject 587 at different time points – exacerbation (exac), 2 weeks 
after exacerbation (pos2), and 6 weeks post exacerbation at clinically recover (recovery) - taxonomic 
composition is shown at phyla level. Each column in the plot represents a time of sample collection, 
and each color in the column represents the relative abundance of each taxon group at phyla level. The 
phyla Firmicutes, Proteobacteria, and Fusobacteria had the higher relative abundance across the three 
times of collection. The relative abundance of Firmicutes is remarkably similar in the three samples. 
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Figure 4. - Samples collect from the subject 526 at different time points – exacerbation (exac),  6 
weeks post exacerbation at clinically recover (recovery), and 8 months after exacerbation (recovery_B) 
- taxonomic composition is shown on phyla level. Each column in the plot represents a time of sample 
collection, and each colour in the column represents the relative abundance of each taxon group at 
phyla. Proteobacteria and Firmicutes were the phyla with higher relative abundances. At “Exac” 
Proteobacteria represents 50% of all the phyla at the sample, and this percentage increases over time. 
The phyla composition of the two samples collected at recovery is rearkably different. 
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Figure 5. - Samples collect from the subject 555 at two different time points – exacerbation (Exac), 2 
weeks after exacerbation (Pos2) - taxonomic composition is shown on phyla level. Each column in the 
plot represents a time of sample collection, and each color in the column represents the relative 
abundance of each taxon group at phyla level. Firmicutes, Actinobacteria, and Proteobacteria are the 
main phyla across the two samples. The relative abundance of Firmicutes increases at “Pos2”, while 
the relative abundances of Actinobacteria and Proteobacteria decrease over time. 
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Figure 6. - Samples collect from the subject E44 at two different time points – exacerbation (Exac) and 
6 weeks post exacerbation at clinically recovery (Recovery) - taxonomic composition is shown on 
phyla level. Each column in the plot represents a time of sample collection, and each colour in the 
column represents the relative abundance of each taxon group at phyla level. The most abundant 
phyla were Firmicutes and Proteobacteria. The relative abundance of Firmicutes decreases at 
“recovery”, while the relative abundance of Proteobacteria increases 
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Figure 7. - Samples collect from the subject 616 at two different time points – exacerbation (Exac) and 6 
weeks post exacerbation at clinically recover (Recovery) - taxonomic composition is shown on phyla level. 
Each column in the plot represents a time of sample collection, and each colour in the column represents 
the relative abundance of each taxon group at phyla level. The phyla with higher relative abundances at the 
two collection times were Firmicutes, Proteobacteria, and Actinobacteria. At “Exac” Firmicutes is almost the 
only phyla present in the sample, while at “Recovery” the sample is much more besides Firmicutes has also 
Proteobacteria, Fusobacteria and Actinobacteria.   
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Figure 8. - Samples collect from the subject S29 at two different time points – exacerbation (Exac) and 
6 weeks post exacerbation at clinically recover (Recovery) - taxonomic composition is shown at the 
genera level. Each column in the plot represents a time of sample collection, and each colour in the 
column represents the relative abundance of each taxon group at genera level. Proteobacteria, 
Firmicutes, and Fusobacteria had the higher relative abundances at the two sampling times. The 
relative abundance of Proteobacteria increases over time, while Firmicutes decreases. 
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7. Statistical analysis per taxon at different collection time points    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. – Bar plot showing the significant microbial composition shifts over time (exacerbation – “Exac”, 
two weeks after exacerbation “Pos2” and 6 weeks and 8 months after exacerbation – “Recovery”), using 
ANOVA with the post-hoc test: Games-Howell. Over time there was a decrease in the relative abundance 
of Streptococcus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. – Bar plot showing the significant microbial composition shifts over time (exacerbation – “Exac”, 
two weeks after exacerbation “Pos2” and 6 weeks and 8 months after exacerbation – “Recovery”), using 
ANOVA with the post-hoc test: Games-Howell. There was an increase in the relative abundance of Rothia 
at “Pos2”. 
 
 
Streptococcus  
Rothia  
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Figure 3. – Bar plot showing the significant microbial composition shifts over time (exacerbation – “Exac”, 
two weeks after exacerbation “Pos2” and 6 weeks and 8 months after exacerbation – “Recovery”), using 
ANOVA with the post-hoc test: Games-Howell. There was an increase in the relative abundance of 
Oribacterium at “Pos2”. 
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8. Statistical analysis per taxon at two different time points (phyla 
level)    
 
Figure 1. – Bar plot showing pairwise comparisons of the samples collected at exacerbation (“Exac”) and 
two weeks after exacerbation (“Pos2”), using two sided t-test. At “Pos2” there was an increase in the 
relative abundance of Proteobacteria. 
 
Figure 2 - Bar plot showing pairwise comparisons of the samples collected at two weeks after exacerbation 
(“Pos2”) and 6 weeks and 8 months after exacerbation (“Recovery”), using two sided t-test. At “Recovery” 
there was a decrease in the relative abundance of Actinobacteria. 
Fusobacteria 
Actinobacteria 
126 
 
9. Statistical analysis per taxon at two different time points (genera 
level)    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Bar plot showing pairwise comparisons of the samples collected at exacerbation (“Exac”) and 
two weeks after exacerbation (“Pos2”), using two sided t-test. At “Pos2” there were increases in the 
relative abundances of Oribacterium and Leptotrichia. 
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Figure 2 - Bar plot showing pairwise comparisons of the samples collected at exacerbation (“Exac”) and 6 
weeks and 8 months after exacerbation (“Recovery”), using two sided t-test. At “Recovery” there was a 
decrease in the relative abundance of Streptococcus. 
 
Figure 3 - Bar plot showing pairwise comparisons of the samples collected two weeks after exacerbation 
(“Pos2”) and 6 weeks and 8 months after exacerbation (“Recovery”), using two sided t-test. At “Recovery” 
there was an increase in the relative abundance of Neisseria. 
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Figure 4 - Bar plot showing pairwise comparisons of the samples collected two weeks after exacerbation 
(“Pos2”) and 6 weeks and 8 months after exacerbation (“Recovery”), using two sided t-test. At “Recovery” 
there were a decrease in the relative abundances of Rothia, Oribacterium, and Veillonella. 
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